Holiday Notification: Cayman Chemical will be closed Monday, September 6, 2010, in observance of the Labor Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, September 7, 2010. Thank you for your patience.
Research Area · Atherosclerosis
· See all 100+ product categories
| Item Number | Product | Sizes & Pricing | CAS | Purity | Image | Exclusive | Introduction Date | Mojo | Plain Text Name | Synonyms | Keywords |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 19500 |
11- |
67910-12-7 | ≥98% |
|
45.313723756906 | 11-dehydro-thromboxane-b2 | 11-keto TXB2; 11-dehydro TXB2 | metabolites thromboxanes plasma 11-dehydro-TXB2 11-keto-TXB2 atherosclerosis | |||
| 319500 |
11- |
- | ≥99% deuterated product |
|
25.313038674032 | 11-dehydro-thromboxane-b2-d4 | 11-keto TXB2-d4 | GC/MS deuterium isotopes 11-dh-TXB2-d4 internal standards thromboxanes 11-dehydro-TXB2-d4 deuterated GC-MS LC/MS LC-MS mass spectrometry atherosclerosis | |||
| 519501 |
11- |
- |
|
202.914777163904 | 11-dehydro-thromboxane-b2-eia-kit | 11-dehydro Thromboxane B2 ELISA Kit | 11-dehydro-TXB2 enzyme immunoassays ELISAs kits measures atherosclerosis metabolites thromboxanes eias atherosclerosis assays | ||||
| 10007239 |
11- |
67910-12-7 | ≥98% |
|
2009-01-16 | 12.293054459352 | 11-dehydro-thromboxane-b2-lipid-maps-ms-standard | 11-dehydro TXB2; 11-keto TXB2 | metabolites thromboxanes plasma 11-dehydro-TXB2 11-keto-TXB2 atherosclerosis MS mass spectrometry standards | ||
| 10006831 |
11- |
- |
|
2005-08-08 | 16.311049723757 | 11-dehydro-thromboxane-b2-quant-pak | Quant-PAKs metabolites thromboxanes plasma deuterium isotopes 11-dh-TXB2-d4 internal standards 11-dehydro-TXB2-d4 deuterated GC/MS GC-MS LC/MS LC-MS mass spectrometry atherosclerosis packs | ||||
| 160304 |
12- |
- | 52.140883977900 | 12-lipoxygenase-murine-leukocyte-polyclonal-antiserum | 12-LO; 12-LOX | 12-LOs leukocyte 12-lipoxygenases western blots blotting WB antisera antibodies antiserum atherosclerosis immunoblotting | |||||
| 34590 |
12(S)- |
54397-84-1 | ≥97% |
|
81.760847145487 | 12-s-hhtre | 12(S)-HHT | platelets thromboxanes hydroxy acids 12S-HHTrEs 12-HHTrEs fatty atherosclerosis | |||
| 10007250 |
12(S)- |
54397-84-1 | ≥97% |
|
2009-02-26 | 56.618259668508 | 12-s-hhtre-lipid-maps-ms-standard | 12-HHT | platelets thromboxanes hydroxy acids 12S-HHTrEs 12-HHTrEs fatty atherosclerosis MS mass spectrometry standards | ||
| 10010425 |
13,14- |
- | >98% |
|
✓ | 2008-05-09 | 0.652223756906 | 13-14-dihydro-15-keto-prostaglandin-d1 | 13,14-dihydro-15-keto PGD1 | PGD1 prostaglandins metabolites DGLA dihomo-.gamma.-linolenic acid dihomo-gamma-linolenic dihomo-y-linolenic PGDs pathways | |
| 38601 |
(±)13- |
167354-91-8 | >98% |
|
2.652044198895 | -13-hode-cholesteryl-ester | atherosclerosis LDL oxidized lipids autoxidation hydroxy fatty acids (+/-)13-HODEs esters racemic | ||||
| 38606 |
13(R)- |
- | >98% |
|
0.495395948434 | 13-r-hode-cholesteryl-ester | atherosclerosis LDL oxidized lipids autoxidation hydroxy fatty acids 13-HODEs 13R-HODEs esters | ||||
| 38611 |
13(S)- |
- | >98% |
|
6.375096685082 | 13-s-hode-cholesteryl-ester | atherosclerosis LDL oxidized lipids autoxidation hydroxy fatty acids 13-HODEs 13S-HODEs esters 13(S)HODEs 13(S)-HODEs | ||||
| 39620 |
13(S)- |
87984-82-5 | >98% |
|
2.929613259668 | 13-s-hotre | linolenic acids hydroxy metabolites 13S-HOTrEs 13-HOTrEs fatty 13(S)-HOTrEs 13(S)HOTrEs | ||||
| 48610 |
13(S)- |
33964-75-9 | >98% |
|
50.196077348066 | 13-s-hpode | linoleic hydroperoxides 13S-HpODEs 13-HpODEs hydroperoxy fatty acids 13(S)-HpODEs | ||||
| 18570 |
15- |
87893-55-8 | ≥97% |
|
200.630168815224 | 15-deoxy-12-14-prostaglandin-j2 | 15-deoxy-Δ12,14-PGJ2 | PPARγ PPARgamma prostaglandins 15-deoxy-delta12,14-PGJ2 15-deoxy-d12,14-PGJ2 nuclear receptors 15-deoxy-Δ12,14-PGJ2 peroxisome proliferator-activated receptors PPARs activators ligands atherosclerosis | |||
| 318570 |
15- |
- | ≥99% deuterated product |
|
67.177668508287 | 15-deoxy-12-14-prostaglandin-j2-d4 | 15-deoxy-Δ12,14-PGJ2-d4 | GC/MS deuterium isotopes 15-deoxy-DELTA12,14-PGJ2-d4 15-deoxy-.DELTA.12,14-PGJ2-d4 15-deoxy-D12,14-PGJ2-d4 internal standards prostaglandins deuterated mass spectrometry GC-MS LC-MS LC/MS atherosclerosis | |||
| 10007235 |
15- |
87893-55-8 | ≥97% |
|
2009-01-16 | 59.648176795580 | 15-deoxy-12-14-prostaglandin-j2-lipid-maps-ms-standard | 15-deoxy-Δ12,14-PGJ2 | PPARγ PPARgamma prostaglandins 15-deoxy-delta12,14-PGJ2 15-deoxy-d12,14-PGJ2 nuclear receptors 15-deoxy-Δ12,14-PGJ2 peroxisome proliferator-activated receptors PPARs activators ligands atherosclerosis MS mass spectrometry standards | ||
| 160704 |
15- |
- |
|
36.354337016574 | 15-lipoxygenase-1-rabbit-polyclonal-antiserum | 15-LO-1; 15-LOX-1 | 15-LOs antibody Western blots 15-lipoxygenases blotting antisera antiserum antibodies atherosclerosis WB immunoblotting | ||||
| 10010468 |
15- |
928853-86-5 | ≥98% |
|
✓ | 2008-10-23 | 24.712417127071 | 15-lipoxygenase-inhibitor-1 | 15-LO Inhibitor 1 | 15-LOs inhibitors inhibits inhibition oxidation inflammation thrombosis cancers lipoxygenases pyrimidobenzothiazine antioxidants | |
| 13076 |
16(R)- |
- | ≥98% |
|
2008-10-10 | 24.321151012891 | 16-r-iloprost | prostacyclin platelet aggregation IP receptors EP vasodilation pulmonary hypertension stereoisomers inhibits inhibitors inhibition iloprosts PGI2 | |||
| 13077 |
16(S)- |
74843-14-4 | ≥98% |
|
2008-10-10 | 24.321151012891 | 16-s-iloprost | prostacyclin platelet aggregation IP receptors EP vasodilation pulmonary hypertension stereoisomers iloprosts inhibits inhibitors inhibition PGI2 | |||
| 10010164 |
1- |
52977-29-4 | ≥95% |
|
✓ | 2008-06-04 | 10.674953959484 | 1-octadecyl-lysophosphatidic-acid | 1-Octadecyl LPA | LPAs lysophosphatidic cells proliferation smooth muscles platelet aggregation neurite proteins sn-1 aggregating | |
| 10010291 |
1- |
- | >95% |
|
✓ | 2008-03-17 | 19.813996316758 | 1-octadecyl-lysophosphatidic-acid-sodium-salt | 1-Octadecyl LPA (sodium salt) | LPA G-proteins receptors cell proliferations smooth muscle contractions platelet aggregations cell motility EDG receptors | |
| 10009431 |
1- |
- | 99% deuterated product |
|
✓ | 2009-07-24 | 3.471491712707 | 1-stearoyl-2-arachidonoyl-pc-d8 | SAPC-d8; 1-Stearoyl-2-Arachidonoyl Phosphatidylcholine-d8 | SAPC LDL oxidation inflammation cardiovascular disease phospholipids LC/MS GC/MS deuterated deuteriums mass spectrometry MS LC-MS GC-MS standards | |
| 515121 |
2,3- |
- |
|
2006-05-23 | 162.024033149171 | 2-3-dinor-6-keto-prostaglandin-f1-eia-kit | 2,3-dinor-6-keto PGF1α ELISA Kit | enzymes immunoassays Prostaglandins PGI2 prostacyclin vascular myocardial infarction inhibits cyclooxygenases atherosclerosis stroke COX-2 measures kits PGF1a assays | |||
| 519051 |
2,3- |
- |
|
125.894254143646 | 2-3-dinor-thromboxane-b2-eia-kit | 2,3-dinor Thromboxane B2 ELISA Kit | 2,3-dinor-TXB2 metabolites thromboxanes measures kits eias enzyme atherosclerosis immunoassays ELISAs assays | ||||
| 13221 |
3- |
- | ≥98% |
|
2009-06-05 | 8.798011049723 | 3-hexanoyl-nbd-cholesterol | 3-C6-NBD Cholesterol | fluorescent cholesterol NBD fluorophore membrane lipids flourescently-tagged probes | ||
| 9000368 |
3- |
- | ≥99% deuterated product |
|
✓ | 2009-04-20 | 7.077900552485 | 3-hydroxy-3-methylglutaryl-coenzyme-a-d3-ammonium-salt | HMG-CoA-d3 | HMG-CoA mevalonic acid mevalonate cholesterol steroids sterols deuterateds deuterium standards GC MS LC mass spetrometry | |
| 90500 |
3- |
116296-31-2 | >98% |
|
2004-02-06 | 1.241613259668 | 3-thiatetradecanoic-acid | 3-TDA | thioether myristic analogs PPAR ligands peroxisome proliferator-activated receptors oleic acids D9-desaturases .DELTA.9-desaturases DELTA9-desaturases atherosclerosis | ||
| 13265 |
4- |
1011268-23-7 | ≥98% |
|
✓ | 2010-06-16 | 0E-12 | 4-hydroxy-nonenal-alkyne | Click Tag™ 4-HNE alkyne | lipids peroxidation inflammation neurodegeneration atherosclerosis diabetes cancers click chemistry Click Tag™ 4-HNEs alkynes IT | |
| 60402 |
5- |
- | cell lysate 16,000 x g supernatant | 33.767895529884 | 5-lipoxygenase-human-recombinant | 5-LO; 5-LOX | 5-LOs enzymes 5-lipoxygenases atherosclerosis | ||||
| 10007820 |
5- |
- | 2006-09-13 | 4.215519839276 | 5-lipoxygenase-phospho-ser523-polyclonal-antibody | 5-LO (Phospho-Ser523) Polyclonal Antibody | wb western blotting blots antibodies regulation leukotrienes asthma fibrosis atherosclerosis inflammation regulating phospho-specific immunoblotting | ||||
| 160402 |
5- |
- |
|
41.979005524862 | 5-lipoxygenase-polyclonal-antibody | 5-LO; 5-LOX | 5-LOs LTA4 asthma 5-lipoxygenases leukotrienes antisera western blots blotting WB antibodies antiserum icc immunocytochemistry atherosclerosis immunoblotting ihc immunohistochemistry | ||||
| 10007601 |
5α- |
13027-33-3 | >98% |
|
2005-11-11 | 225.631675874769 | 5-hydroxy-6-keto-cholesterol | 6-Oxo-3,5-diol; Cholestane-6-oxo-3β,5α-diol | atherosclerosis cholesterols ozonolysis cytotoxicity metabolites ozone-oxidized lipids surfactants lungs epithelials lining fluids exposures cells bronchalveoalar lavaged homogenates inhibits inhibitors synthesis bronchial cytotoxicity toxic oxysterols hydroxycholesterol | ||
| 15210 |
6- |
58962-34-8 | >99% |
|
73.638353591160 | 6-keto-prostaglandin-f1 | 6-keto PGF1α | PGI2 metabolites prostaglandins 6-keto-PGF1alpha 6-keto-PGF1.alpha. atherosclerosis | |||
| 315210 |
6- |
- | ≥99% deuterated product |
|
16.921370165746 | 6-keto-prostaglandin-f1-d4 | 6-keto PGF1α-d4 | GC/MS deuterium isotopes 6-keto-PGF1a-d4 6-keto-PGF1alpha-d4 6-keto-PGF1.alpha.-d4 internal standards prostaglandins PGFα deuterated LC/MS GC-MS LC-MS mass spectrometry d4 atherosclerosis | |||
| 515211 |
6- |
- |
|
353.000810313075 | 6-keto-prostaglandin-f1-eia-kit | 6-keto Prostaglandin F1α ELISA Kit | solid plates 6-keto-PGF1alpha 6-keto-PGF1.alpha. prostaglandins measures kits eias atherosclerosis enzyme immunoassays ELISAs 6-keto Prostaglandin F1.alpha. EIA Kit assays | ||||
| 10007219 |
6- |
58962-34-8 | >99% |
|
2008-12-17 | 41.464121546961 | 6-keto-prostaglandin-f1-lipid-maps-ms-standard | 6-keto PGF1α | PGI2 metabolites prostaglandins 6-keto-PGF1alpha 6-keto-PGF1.alpha. atherosclerosis PGs MS mass spectrometry standards | ||
| 10312 |
8,12- |
- | 98% |
|
✓ | 2009-08-07 | 7.755184162062 | 8-12-iso-ipf2-vi-1-5-lactone | lactone IPF2α -I iPF2α-VI F2-iP urine lipid peroxidation plasma biomarker oxidative stress 214894-81-2 214894-83-4 | ||
| 10007850 |
9,11- |
72517-81-8 | >96% |
|
2006-05-10 | 108.126279926335 | 9-11-methane-epoxy-prostaglandin-f1 | 9,11-Epoxymethano PGH1 | prostaglandins PGs endoperoxides TXs thromboxanes prostacyclins PGH1 platelets smooth muscles analogs aggregation aorta aortic tracheas histamines coronary perfusion atherosclerosis | ||
| 38401 |
(±)9- |
33783-76-5 | >98% |
|
3.593793738489 | -9-hode-cholesteryl-ester | atherosclerosis LDL oxidized lipids autoxidation hydroxy fatty acids esters (+/-)9-HODEs (+/-)-HODEs (+/-)HODEs racemic | ||||
| 38406 |
9(R)- |
- | >98% |
|
0.513720073664 | 9-r-hode-cholesteryl-ester | atherosclerosis LDL oxidized lipids autoxidation hydroxy fatty acids esters 9R-HODEs 9-HODEs 9(R)-HODEs 9(R)HODEs | ||||
| 38410 |
9(S)- |
73543-67-6 | >98% |
|
30.824456721915 | 9-s-hode | linoleic acids hydroxy oxidized 9S-HODEs 9-HODEs fatty 9(S)-HODEs 9(S)HODEs | ||||
| 38411 |
9(S)- |
- | >98% |
|
7.385013812154 | 9-s-hode-cholesteryl-ester | atherosclerosis LDL oxidized lipids hydroxy fatty acids 9-HODEs esters 9S-HODEs 9(S)-HODEs 9(S)HODEs | ||||
| 338410 |
9(S)- |
- | >99% deuterated product |
|
27.338950276243 | 9-s-hode-d4 | GC/MS deuterium isotopes 9-HODE-d4 standards 9S-HODE-d4 deuterated GC-MS LC/MS LC-MS 9-HODEs 9(S)-HODEs 9S-HODEs 9(S)HODES hydroxy fatty acids 9(S)HODE-d4 mass spectrometry | ||||
| 100028 |
ACAT- |
- |
|
2004-04-28 | 13.581862667719 | acat-1-polyclonal-antibody | Sterol O-Acyltransferase 1; Acyl-coenzyme A: Cholesterol Acyltransferase-1 | Acyl-coenzyme A: cholesterol acyltransferase-1 esters ACAT1 atherosclerosis antibodies antisera antiserum western blots blotting wb icc immunocytochemistry ihc immunohistochemistry immunoblotting | |||
| 100027 |
ACAT- |
- |
|
2004-04-26 | 12.579392265193 | acat-2-polyclonal-antibody | Sterol O-Acyltransferase 2; Acyl-coenzyme A: Cholesterol Acyltransferase-2 | Acyl-coenzyme A: cholesterol acyltransferase-2 esters ACAT2 atherosclerosis antibodies antisera antiserum western blots blotting wb icc immunocytochemistry ihc immunohistochemistry immunoblotting | |||
| 10007686 | Acetyl Podocarpic Acid Anhydride Exclusive | 344327-48-6 | >98% |
|
✓ | 2007-07-11 | 95.170580110497 | acetyl-podocarpic-acid-anhydride | APD | receptors ABC1 ABCA1 oxysterol cholesterol LXRalpha LXR.alpha. LXRbeta LXR.beta. 7.alpha.-hydroxylase RXR retinoid agonists nuclear receptors atherosclerosis acetyls podocaysics acids anhydrides livers hormones atherosclerosis | |
| 589451 | AcSDKP EIA Kit | - |
|
183.304475138121 | acsdkp-eia-kit | N-Acetyl Ser-Asp-Lys-Pro EIA Kit; AcSDKP ELISA Kit | N-Acetyl-Seryl-Aspartyl-Lysyl-Proline serine aspartamine lysine measures kits eias enzyme immunoassays ELISAs growth regulatory hormones plasma urine spi-bio spibio A05881 atherosclerosis hypertension endocrinology assays | ||||
| 10092 | Adenosine Receptor A2A Blocking Peptide | - | 2009-04-03 | 199.064604051565 | adenosine-receptor-a2a-blocking-peptide | A2AR | blocking peptides Western blots immunoblotting ARA2A | ||||
| 10006908 | Adipogenesis Assay Kit | - |
|
2006-08-18 | 79.845113008538 | adipogenesis-assay-kit | obese obesity cells cycle differentiation inhibits inhibitors inhibition adipocytes cancers origin 3T3-L1 model drug screening adipokines endocrinology cell-based assays cell based assay cba | ||||
| 10009381 | Adipolysis Assay Kit | - |
|
2007-07-30 | 41.588784530386 | adipolysis-assay-kit | obese obesity cells cycle differentiation inhibits inhibitors inhibition adipocytes cancers origin 3T3-L1 model drug screening adipokines lipolysis 3T3L1 kits assays FFA adipocytes endocrinology cell-based assay cell based assay cba | ||||
| 10008492 | Adipose Triglyceride Lipase Blocking Peptide | - | 2006-06-27 | 16.096408839779 | adipose-triglyceride-lipase-blocking-peptide | ATGL; TG-hydrolase inducible PLA2-ζ; Desnutrin | antibodies western blotting blots signaling signalling IHC WB formalin immunohistochemistry controls peptides proteins triglycerides energy storage mammalian adipose tissues caloric excess enzymes mobilization fatty acids catalyzes triacylglycerols diacylglycerols inhibition acylhydrolase activity diabetics pathology lung skeletal muscles testis heart brain kidney cells brown fat livers murine mouse macrophages HepG2 atherosclerosis | ||||
| 10006409 | Adipose Triglyceride Lipase Polyclonal Antibody | - |
|
2005-11-23 | 24.063149171270 | adipose-triglyceride-lipase-polyclonal-antibody | Phospholipase A2ζ; Desnutrin; ATGL | antibodies antisera antiserum WB western blots blotting IHC immunohistochemistry triglycerides energy storage mammalian adipose tissues caloric excess enzymes mobilization fatty acids catalyzes triacylglycerols diacylglycerols inhibition acylhydrolase activity diabetics pathology lung skeletal muscles testis heart brain kidney cells brown fat livers murine mouse macrophages HepG2 atherosclerosis immunoblotting | |||
| 19023 | AH 23848 (calcium salt, hydrate) | - | ≥90% |
|
2009-02-26 | 109.787279005524 | ah-23848-calcium-salt-hydrate | AH23848B AH 23848 TXBs thromboxane PGEs PGE2 receptors prostanoids TPs EP4 antagonist blockers inhibitors inhibits inhibition TXA2 platelets smooth muscle bronchial U-46619 U46619 fibroblasts cancers metastasis 81739-45-9 AH-23848 | |||
| 10010241 | AICAR | 2627-69-2 | >98% |
|
2008-02-25 | 245.893950276243 | aicar | NSC 105823; Acadesine; AICA Riboside | AMPK lipids metabolism glucose fatty acids sterol HMG-CoA reductases inflammation cytokine iNOS COX-2 MnSOD glia macrophages TNF-.alpha. IL-1.beta. IL-6 aminoimidazole carboxamide ribonucleotide | ||
| 589301 | Angiotensin II EIA Kit | - |
|
141.064143646408 | angiotensin-ii-eia-kit | Angiotensin II ELISA Kit | hypertension angiotensin measures kits eias enzyme immunoassays ELISAs spi-bio spibio A05880 atherosclerosis endocrinology assays | ||||
| 10009751 | ApoA1 Western Ready Control | - | 2007-07-11 | 23.863226519337 | apoa1-western-ready-control | Apolipoprotein A1 | western blots WB high-density lipoproteins HDL liver phospholipids excretion steroidogenesis blotting ApoA-1 atherosclerosis | ||||
| 13079 | ApoAI Blocking Peptide | - | 2008-09-30 | 9.689502762431 | apoai-blocking-peptide | Apolipoprotein A-I; Apolipoprotein AI | antibodies antibody peptides antiserum antisera blocking immunoblotting WB western blots | ||||
| 500155 | ApoAI (human) EIA Kit | - |
|
2009-05-12 | 27.081314917126 | apoai-human-eia-kit | Apolipoprotein AI (human) ELISA Kit | 10010551 atherosclerosis EIAs kits ApoA-1 ApoA-I Apo A1 Apo AI ApoA1 Apo-A1 Apo-AI HDL high-density lipoproteins livers intestines phospholipids cholesterols nascent ABCA1 peripheral tissues steroidogenesis myocardial infarction CAD Tangier diseases familial hypolipoproteinemia systemic non-neuropathic amyloidosis immunometric plasma serum levels assays | |||
| 13042 | ApoAI Monoclonal Antibody (Clone CC3821C4) Exclusive | - | ✓ | 2008-10-15 | 17.531325966850 | apoai-monoclonal-antibody-clone-cc3821c4 | Apolipoprotein AI | antibodies HDL high-density lipoproteins WB western blots polypeptide immunoblotting blotting A-I A-1 apopipoproteins | |||
| 10008463 | ApoAI Polyclonal Antibody | - |
|
2006-03-30 | 29.575524861878 | apoai-polyclonal-antibody | Apolipoprotein A-I; Apolipoprotein AI | atherosclerosis proteins diseases antibodies antisera antiserum WB western blotting ICC immunocytochemistry ApoA1 ApoA-1 Apo A-1 Apo A1 Apo AI Apo-A1 Apo-AI blots immunoblotting | |||
| 70260 | Aspirin | 50-78-2 | >99% |
|
3.708852056476 | aspirin | Acetylsalicylic Acid | atherosclerosis cyclooxygenases inhibitors NSAIDs COX-1 COX-2 nonsteroidal anti-inflammatory drugs cox1 cox2 pghs1 pghs2 pghs-1 pghs-2 prostaglandin H synthases synthase-1 synthase-2 inhibits | |||
| 10010153 |
Aspirin™ Effect- |
- |
|
2007-06-08 | 69.497127071823 | aspirin-effect-detection-kit | use:human 11-dehydro-TXB2 enzyme immunoassays ELISAs kits measures metabolites atherosclerosis thromboxanes eias analysistools:eia atherosclerosis cyclooxygenases inhibitors NSAIDs COX-1 COX-2 nonsteroidal anti-inflammatory drugs cox1 cox2 pghs1 pghs2 pghs-1 pghs-2 prostaglandin H synthases synthase-1 synthase-2 inhibits atherosclerosis assays | ||||
| 10005292 | Atherosclerosis Product Pack | - | 2004-09-09 | 6.775257826887 | atherosclerosis-product-pack | Acyl-coenzyme A: cholesterol acyltransferase-1 esters ACAT1 atherosclerosis inhibitors inhibits inhibition CETP WB blots blotting IHC immunohistochemistry JTT-705 89450 packs | |||||
| 589401 | Atriopeptin (rat) EIA Kit | - |
|
24.620883977900 | atriopeptin-rat-eia-kit | Atriopeptin (rat) ELISA Kit | naturiuretic auriculin measures kits eias enzyme immunoassays ELISAs atherosclerosis pi-bio spibio A05103 hypertension endocrinology assays | ||||
| 60924 | Azelaoyl PAF | - | >98% |
|
95.509960536701 | azelaoyl-paf | PPAR gamma oxidized LDL lipids agonist atherosclerosis nuclear receptors | ||||
| 10010266 |
BAY- |
19542-67-7 | ≥98% |
|
2008-07-25 | 37.916053670087 | bay-11-7082 | inhibitors inhibits inhibition NFkB NF-.kappa.B NF-kB NF-kappaB TNF.alpha. TNFa TNFalpha I.kappa.B-.alpha. IkB-a IkappaB-alpha inflammation cytokine cell adhesion ICAM-1 ICAM1 VCAM-1 VCAM1 E-selection Eselection Bay 11-7082 BAY-117821 Bay117082 BAY 117821 | |||
| 18230 | Beraprost (sodium salt) | 88475-69-8 | >98% |
|
126.589881610103 | beraprost-sodium-salt | TRK 100; Procylin; ML 1129 | prostaglandins inhibitors inhibits PGI2 prostacyclin platelets aggregation pulmonary atherosclerosis hypertension analogs salts ML-1129 ML1129 TRK-100 TRK100 Na+ | |||
| 10006427 | Berberine | 633-65-8 | >95% |
|
2005-05-25 | 9.884944751381 | berberine | Umbellatine; BBR | natural alkoloid hypocholesterolemic activity berberidaceaen medicine antiprotozoal antidiahreal agents reduces total cholesterol LDLR low-density lipoproteins triglycerides high fat diet LDL-receptors proteins mRNA levels hepatocytes serum atherosclerosis | ||
| 10009145 | Bezafibrate | 41859-67-0 | >98% |
|
2007-08-02 | 11.961077348066 | bezafibrate | Difaterol; Bezatrol; Bezalip; BM 15075; Benzofibrate | PPAR PPAR.alpha. PPAR.delta. PPAR.gamma. agonist Pan-PPAR cholesterol atherosclerosis metabolic syndromes LDL HDL proliferator-activated receptors diabetes low-density high-density lipoproteins atherosclerosis cardiovascular PPARa PPARd PPARg endocrinology fibrate | ||
| 10010517 | BIBB 515 | 156635-05-1 | ≥98% |
|
2008-06-16 | 0E-12 | bibb-515 | inhibitor inhibits inhibition BIBB515 OSC LDL 2,3-oxidosqualene cyclase cholesterol BIBB-515 | |||
| 120114 | BLT1 Receptor Polyclonal Antibody | - |
|
6.673784530386 | blt1-receptor-polyclonal-antibody | Leukotriene B4 Receptor 1; LTB4 Receptor 1; BLTR1 | LTB4R1 receptors antiserum antibodies leukotrienes neutrophils inflammation antisera flow cytometry immunocytochemistry icc WB western blots blotting immunohistochemistry ihc atherosclerosis immunoblotting FC | ||||
| 100019 | BLT1 Receptor Polyclonal Antiserum | - | 4.624935543277 | blt1-receptor-polyclonal-antiserum | Leukotriene B4 Receptor 1; LTB4 Receptor 1; BLTR1 | C-terminus C-terminal intracellular plasma membranes whole cells LTB4R1 receptors antiserum antibodies leukotrienes neutrophils inflammation antisera flow cytometry immunocytochemistry icc WB western blots blotting immunohistochemistry ihc chronic pancreatitis pancreatic cancers pancreas atherosclerosis immunoblotting FC | |||||
| 120124 | BLT2 Receptor Polyclonal Antibody | - |
|
122.405252868678 | blt2-receptor-polyclonal-antibody | Leukotriene B4 Receptor 2; LTB4 Receptor 2; BLTR2 | LTB4R2 LTB4-R2 receptors antiserum antibodies leukotrienes neutrophils inflammation antisera western blots blotting WB atherosclerosis immunoblotting | ||||
| 10155 | BM 567 | 284464-77-3 | >98% |
|
2005-03-31 | 35.087377815554 | bm-567 | platelets thromboxanes TXA2 atherosclerosis synthases inhibits inhibition inhibitors antagonists BM567 BM-567 thrombogenic vasocontrictors TP receptors eicosanoids strokes myocardial infarctions GPCR vascular smooth muscles protein-coupled license:liege | |||
| 60928 | Butanoyl PAF | - | >98% |
|
9.720939226519 | butanoyl-paf | ox-LDL signaling molecules oxLDL oxidized low-density lipoproteins PMNL polymorphonuclear leukocytes platelet-activating factors atherosclerosis | ||||
| 60929 | Butenoyl PAF | - | >98% |
|
10.307756906077 | butenoyl-paf | ox-LDL signaling molecules oxLDL oxidized low-density lipoproteins PMNL polymorphonuclear leukocytes platelet-activating factors atherosclerosis | ||||
| 13285 | Cannabidiol dimethyl ether | 1242-67-7 | ≥98% |
|
2009-05-19 | 6.635718232043 | cannabidiol-dimethyl-ether | Cannabidiol-2',6'-dimethyl ether; CBDD | 15-lipoxygenases 15-LOs dioxygenase fatty acids inflammation thrombosis cancer LDL oxidation inhibitions inhibition inhibiting | ||
| 18210 | Carbaprostacyclin | 69552-46-1 | >99% |
|
26.659378453039 | carbaprostacyclin | Carbacyclin; cPGI | analogs vasodilation PPARs peroxisome proliferator-activated receptors PGI2 prostaglandins atherosclerosis cPGI Carbacyclin | |||
| 19010 | Carbocyclic Thromboxane A2 | 74034-56-3 | >98% |
|
7.281436464088 | carbocyclic-thromboxane-a2 | CTA2; Carbocyclic TXA2 | thromboxanes analogs TXA2 vasoconstriction CTA2 atherosclerosis | |||
| 13187 | Cardiogenol C (hydrochloride) | 671225-39-1 | ≥97% |
|
2009-02-06 | 8.373922651933 | cardiogenol-c-hydrochloride | Embryonic stem cells Differentiation Cardiomyocytes Cardiac muscle GATA-4 MEF2 Nkx2.5 | |||
| 10005186 | CAY10441 Exclusive | 221529-58-4 | >98% |
|
✓ | 2004-09-16 | 112.584337016574 | cay10441 | RO1138452 | receptors antagonists IPs prostaglandins carbaprostacyclins inhibits inhibitors inhibition analgesics high-affinity ligands neuroblastoma cyclic AMP cAMP adenylate cyclase 4,5-dihydro-1H-imidazol-2-yl-4-4-isopropoxy benzyl phenylamine atherosclerosis | |
| 10005913 | CAY10449 Exclusive | - | >98% |
|
✓ | 2004-10-26 | 202.691795580110 | cay10449 | receptors antagonists IPs prostaglandins carbaprostacyclins inhibits inhibitors inhibition analgesics high-affinity ligands neuroblastoma adenylate cyclase cyclic AMP cAMP iloprost athersclerosis CAY 10449 | ||
| 10006482 | CAY10485 | 615264-62-5 | >98% |
|
2005-05-03 | 5.145603788476 | cay10485 | 3,4-dihydroxy Hydrocinnamic acid (L-Aspartic acid dibenzyl ester) amide | atherosclerosis antioxidants dihydrocinnamic acids LDLs low density lipoproteins cholesterols acyl-coenzyme A: cholesterol acyltransferase-1 catalyzes esters ACAT-1 ACAT-2 low density lipoproteins oxidations ACAT1 ACAT2 | ||
| 10006452 | CAY10486 | 615264-52-3 | >98% |
|
2005-05-09 | 6.406224677716 | cay10486 | 4-Hydroxycinnamic acid (L-phenylalanine methyl ester) amide | atherosclerosis antioxidants dihydrocinnamic acids LDLs cholesterols acyl-coenzyme A:cholesterol acyltransferase-1 catalyzes esters ACAT-1 ACAT-2 low density lipoproteins oxidations ACAT1 ACAT2 | ||
| 10006480 | CAY10487 | 778624-05-8 | >98% |
|
2005-03-29 | 6.549871086556 | cay10487 | 3,4-Dihydrocinnamic Acid (L-alanine methyl ester) amide | atherosclerosis antioxidants dihydrocinnamic acids LDLs cholesterols low-density lipoproteins foam cells fatty streaks arterial walls lesions thoracic aortas lipids ACAT-1 ACAT-2 ACAT1 ACAT2 | ||
| 10007875 | CAY10499 Exclusive | 359714-55-9 | >98% |
|
✓ | 2006-07-25 | 23.061418047882 | cay10499 | obesity lipases diabetes triglycerides diacylglycerol inhibitors steroidogenesis spermatogenesis atherosclerosis HSL hormone sensitive endocrinology | ||
| 10009536 | CAY10512 | 139141-12-1 | >97% |
|
2007-07-18 | 12.972464088398 | cay10512 | analogs resveratrol nuclear factors NFkB NF-.kappa.B immunity inflammation stress growth apoptosis trans-stilbene activation cancers NF-kB inhibition inhibtors inhibits atherosclerosis | |||
| 10009017 | CAY10514 | 868526-38-9 | >98% |
|
2007-01-24 | 3.903121546961 | cay10514 | Methyl-8-hydroxy-8-(2-pentyl-oxyphenyl)-oct-5-ynoate | peroxisome proliferator-activated receptors aromatics analogs 8-HETEs 8S-HETE 8(S)-HETE agonists PPARa PPARalpha PPAR.alpha. PPARg PPARgamma PPAR.gamma.atherosclerosis | ||
| 16835 | CAY10580 Exclusive | 64054-40-6 | ≥96% |
|
✓ | 2009-03-16 | 191.022872928176 | cay10580 | PGEs PGE2 receptors inhibitors inhibits inhibition antagonist blockers EP4 cAMPs bones fromation resorption cancers atherosclerosis | ||
| 10012424 | CAY10583 Exclusive | 862891-27-8 | ≥98% |
|
✓ | 2009-07-21 | 101.415285451197 | cay10583 | LTB4 leukotrienes B4 LTBs BLT1 BLT2 BLTs agonist aggregation inflammation increases calcium intracellular stores induces ERK phosphorylation | ||
| 13181 | CAY10590 Exclusive | 1101136-50-8 | ≥98% |
|
✓ | 2009-04-15 | 28.378545119704 | cay10590 | sPLA2 cPLA2 iPLA2 phospholipases inhibitors R-gamma-nonleucine inhibition inhibited secreetory regulates phagocytosis foam cells | ||
| 10012536 | CAY10592 Exclusive | 685139-10-0 | ≥98% |
|
✓ | 2009-02-26 | 57.083535911601 | cay10592 | selective PPARδ agonist HDLs LDLs TGs lipids metanolism plasma rats L6 cells lines APOB100 CETP-Tgn mice mouse transactivation assays CETPTgn CETP Tgn | ||
| 13281 | CAY10598 Exclusive New | 346673-06-1 | ≥98% |
|
✓ | 2010-05-07 | 28.830165745856 | cay10598 | Prostaglandins E2 PGE2 receptors EP4 bone formation cancers atherosclerosis agonists EP1 EP2 EP3 DP FP IP TP neuroprotection renal dysfunction inflammation neuro-protection | ||
| 13282 | CAY10599 Exclusive | 1143573-33-4 | ≥98% |
|
✓ | 2009-07-21 | 79.739828115408 | cay10599 | thiazolidinedione PPARs PPARγ agonist rosiglitazones BRL 49653 BRL49653 BRL-49653 diabetes TZDs | ||
| 188150 | CD36 Monoclonal Antibody (Clone JC63.1) | - | 36.202174427781 | cd36-monoclonal-antibody-clone-jc63-1 | Thrombospondin Receptor; oxLDL Receptor; Hexarelin Receptor; GPIV; GPIIIb | antibodies antisera antiserum flow cytometry PPAR.gamma. CD-36 glycoprotein fatty acids PPARgamma blocking apoptosis oxidative injury atherosclerosis FC | |||||
| 10009893 | CD36 Monoclonal Antibody (Clone JC63.1) (azide free) | - | 2010-03-03 | 106.303264491800 | cd36-monoclonal-antibody-clone-jc63-1-azide-free | GPIV; oxLDL; Thrombospondin Receptor; Hexarelin Receptor; GPIIIb | antibodies antisera antiserum flow cytometry PPAR.gamma. CD-36 glycoprotein fatty acids PPARgamma blocking apoptosis oxidative injury atherosclerosis FC leukemia lymphocytic | ||||
| 10009870 | CD36 Monoclonal FITC Antibody (Clone JC63.1) | - | 2008-03-17 | 38.674479742172 | cd36-monoclonal-fitc-antibody-clone-jc63-1 | Thrombospondin Receptor; Hexarelin Receptor; GPIIIb; OxLDL Receptor; GPIV | type-B atherosclerotic lesions fatty acids PPAR.gamma. expression flow cytometry immunocytochemistry FC ICC | ||||
| 100011 | CD36 Polyclonal Antibody | - |
|
25.232320441989 | cd36-polyclonal-antibody | Thrombospondin Receptor; oxLDL Receptor; Hexarelin Receptor; GPIV; GPIIIb | type scavengers receptors atherosclerotic lesions glycoprotiens membranes PPAR.gamma. PPARgamma antibodies atherosclerosis CD-36 western blots blotting peroxisome proliferator-activated GP-IIIb GP-IV GP-3b GP-4 WB atherosclerosis immunoblotting | ||||
| 10010250 | Cellular Retinol Binding Protein 7 Polyclonal Antibody | - |
|
2007-10-16 | 5.420530386740 | cellular-retinol-binding-protein-7-polyclonal-antibody | Retinoid Binding Protein 7; cRBP7; RET7; Cellular Retinol Acid-Binding Protein IV | western blots WB ICC immunocytochemistry micronutrient cell growth differentiation CRBPs RBP4 RBP7 atherosclerosis blotting immunoblotting IHC immunohistochemistry | |||
| 10007171 | Cetaben | 55986-43-1 | >98% |
|
2005-11-11 | 8.904295580110 | cetaben | Hexadecylamino-p-amino Benzoic Acid | clofibrate peroxisomes proliferator-activated receptors PPARalpha PPAR.alpha.-independent hypolipidemic activity reduces reduction serums triglycerides cholesterols concentrations peroxisomal enzymes inhibits synthesis hepatoma HepG2 cells reversible changes Golgi morphology blocked esters inhibitors fibrates class atherosclerosis endocrinology | ||
| 10012447 | CG 4305 New | - | ≥95% |
|
2010-05-12 | 0E-12 | cg-4305 | antithrombotic PGI2 epoprostenol prostacyclins platelets aggregation 89955-40-8 PGs prostaglandins I2 cartoid artery thrombosis inhibits inhibited inhibition inhibitory | |||
| 10325 |
Chemokine- |
- |
|
2010-01-25 | 83.827059545733 | chemokine-like-receptor-1-polyclonal-antibody | ChemR23; CMKLR1; DEZ; ChemerinR; Resolvin E1 Receptor; GPCR ChemR23 | immunohistochemistry antibodies western blots WB IHC ChemerinR immunoblotting blotting DEZ ChemerinR | |||
| 10011286 | Chenodeoxycholic Acid | 474-25-9 | ≥95% |
|
2009-02-25 | 0.099447513812 | chenodeoxycholic-acid | Ulmenide; Kebilis; Anthropodeoxycholic Acid; Hekbilin; Fluibil; CDCA | FXR biles acids cholesterol oxidative stress glutathione cancers atherosclerosis diabetes hyperlipidemia CDA | ||
| 10007640 | Cholesterol Assay Kit | - |
|
2006-02-28 | 109.417734806629 | cholesterol-assay-kit | Fluorescence Kits Metabolism coronary heart diseases LDL lipoproteins ADHP atherosclerosis assays fluorescent fluorometric | ||||
| 10009779 |
Cholesterol Cell- |
- |
|
2007-05-04 | 60.875331491712 | cholesterol-cell-based-detection-assay-kit | Fluorescence Kits Metabolism coronary heart diseases LDL lipoproteins ADHP atherosclerosis fluorescent fluorometric assays cell-based assay cell based assays cba | ||||
| 48001 | Cholesteryl Linoleate Hydroperoxides | - | >98% hydroperoxide content |
|
11.495767955800 | cholesteryl-linoleate-hydroperoxides | autoxidation atherosclerosis LDL HDL hydroperoxy fatty acids | ||||
| 10010060 |
ChREBP Cell- |
- |
|
2007-08-15 | 12.783215469613 | chrebp-cell-based-translocation-assay-kit | Carbohydrate Response Element-Binding Protein Cell-Based Translocation Assay Kit | assays kits transcription factors TFs diabetes nutrients hormones hormonal regulation genes encoding enzymes glucose metabolisms lipogenesis dephosphorylated cytoplasm protein Ser196 nucleus liver obesity tolerance drugs discovery modulators sub-cellular localization ICC immunocytochemical stains staining antibody antibodies DyLightTM Pierce Biotechnology Inc. fluorescence fluorescent fluorometric endocrinology cell-based assay cell based assay cba | |||
| 10006909 | ChREBP Transcription Factor Assay Kit | - |
|
2006-07-12 | 41.637783149171 | chrebp-transcription-factor-assay-kit | Carbohydrate Response Element-Binding Protein | tf chrebps carbohydrate response element binding protein glucose liver insulin obesity adipokines endocrinology assays | |||
| 71730 | Ciglitazone | 74772-77-3 | >98% |
|
124.729377197388 | ciglitazone | U-63287; ADD 3878 | nuclear receptors antidiabetic diabetes thiazolidinedione PPAR gamma PPAR.gamma. Peroxisome Proliferator-activated receptors Ligands Binding domains antihyperglycemic atherosclerosis endocrinology | |||
| 18216 | Ciprostene (calcium salt) | 81703-55-1 | >98% |
|
27.655174953959 | ciprostene-calcium-salt | U-61431F; Ciprostene calcium | PGI2 analogs vasodilation 9.beta.-methyl 9beta-methyl carbaprostacyclin prostaglandins salts cat U61431F atherosclerosis | |||
| 10004235 |
cis- |
61434-67-1 | >98% (may contain 1-5% trans) |
|
2008-02-05 | 26.430033149171 | cis-resveratrol | (Z)-Resveratrol | antioxidant oxidative stress reactive oxygen species reactive nitrogen species ROS RNS NF-kb inflammations monoamine oxidase noradrenaline inhibits inhibitor inhibitions NF.kappa. atherosclerosis sirtuins | ||
| 10005745 | Clofibrate | 637-07-0 | >98% |
|
2004-09-14 | 19.326398794575 | clofibrate | PPAR.alpha. PPARalpha ligands selective peroxisome proliferator-activated nuclear receptors lipids dyslipidemia fatty acids b-oxidation beta-oxidation .beta.-oxidation hypolipidemic drugs cardiovascular diseases homeostasis agonists selectivity atherosclerosis endocrinology fibrate | |||
| 160110 |
COX- |
- |
|
82.154979742173 | cox-1-monoclonal-antibody-clone-cx111 | PGHS-1; Prostaglandin H Synthase 1; Cyclooxygenase 1 | prostaglandins inflammation cancer arthritis antibodies cox1 pghs1 pghs-1 synthases cyclooxygenases western blots blotting WB antisera antiserum immunohistochemistry IHC immunocytochemistry ICC antisera antiserum atherosclerosis immunoblotting | ||||
| 160109 |
COX- |
- |
|
42.842734806629 | cox-1-murine-polyclonal-antibody | PGHS-1; Prostaglandin H Synthase 1; Cyclooxygenase 1 | prostaglandins inflammation cancer arthritis antibodies mouse cox1 pghs1 pghs-1 cyclooxygenase-1 cyclooxygenases synthase-1 synthases antiserum antisera western blots blotting wb IHC immunohistochemistry atherosclerosis immunoblotting | ||||
| 10011236 |
C- |
- |
|
2009-04-22 | 374.940878453039 | c-reactive-protein-human-eia-kit | CRP (human) EIA Kit | atherosclerosis proteins hepatocytes adipocytes plasma blood inflammatory inflammation physiological pathological atherogenesis endothelial coagulation ICAM-1 VCAM-1 E-selectin LDL macrophages plaques immunometric assays enzyme immunoassay ELISAs | |||
| 120500 | CysLT1 Receptor Polyclonal Antibody | - | 69.742602209944 | cyslt1-receptor-polyclonal-antibody | Cysteinyl Leukotriene Receptor 1 | cysteinyl-leukotrienes receptors antibodies LTC4 LTD4 LTE4 Cys-LT1 human flow cytometry asthma peptido-leukotrienes FACS antisera immunochemistry icc immunohistory ihc antiserum wb western blotting blots atherosclerosis immunoblotting immunocytochemistry immunohistochemistry FC | |||||
| 10012577 | Diallyl Trisulfide | 2050-87-5 | ≥98% |
|
2009-04-07 | 2.760220994474 | diallyl-trisulfide | DATS; NSC 651936 | garlic hydrogen sulfides H2S cancers tumors smooth muscle cholesterol atherosclerosis donors supresses colon synthesis genes expression adenocarcinomas HCT-15 cells PC-3 xenografts | ||
| 62237 |
Diphenyl- |
110231-30-6 | >98% |
|
2006-07-25 | 62.428694751381 | diphenyl-1-pyrenylphosphine | DPPP | hydroperoxides oxidative stress injury fluorescence fluorescent lipids cholesterols LDL oxidation DPPPO DPPP=O atherosclerosis | ||
| 10005057 |
Docosahexaenoic Acid- |
- | ≥99% deuterated product |
|
2005-03-16 | 66.514917127071 | docosahexaenoic-acid-d5 | DHA-d5; Cervonic Acid-d5 | standards deuterium internal isotopes GC/MS GC-MS LC/MS LC-MS mass spectrometry deuterated polyunsaturated fatty acids PUFAs omega-3 brain .omega.-3 w-3 retinol neuronal membranes neonatal deprivation hypertension | ||
| 9090310 | Docosahexaenoic Acid ethyl ester | 1020718-25-5 | ≥98% |
|
2009-01-15 | 32.654212707182 | docosahexaenoic-acid-ethyl-ester | DHA ethyl ester; Cervonic Acid ethyl ester | fish oils anti-inflammatory antiiflammatory cardiovascular polyunsaturated fatty acids PUFAs DHAs neural tissues retina brain learning diet nutrition oxidation vision liver function muscle tone competitive inhibitors inhibits inhibition metabolism | ||
| 101640 | DP1 Receptor Polyclonal Antibody | - |
|
2004-10-22 | 27.251933701657 | dp1-receptor-polyclonal-antibody | Prostaglandin D2 Receptor 1; PGD2 Receptor 1 | isoforms prostaglandins PGs PGD2 cyclooxygenase metabolites G-protein coupled receptors GPCR cyclic cAMP Ca2+ calcium western blots blotting WB immunocytochemistry ICC immunohistochemistry IHC COX antibodies antiserum antisera atherosclerosis immunoblotting | |||
| 10011296 |
(E)- |
39025-24-6 | ≥98% |
|
2009-12-03 | 0.471069135434 | -e-guggulsterone | anti-flammatory cancers FXR bile acids LDL cholesterol antiinflammatory atherosclerosis obesity diabetes inflammation farnesoid X receptors guggul trees | |||
| 10008884 | Eicosapentaenoic Acid ethyl ester | - | ≥98% |
|
2009-01-29 | 38.797624309392 | eicosapentaenoic-acid-ethyl-ester | EPA-EE; EPA ethyl ester | fish oils anti-inflammatory anitinflammatory cardiovascular polyunsaturated fatty acids PUFAs EPAs nutrition oxidation competitive inhibitors inhibits inhibition metabolism cholesterol triglycerides insulin resistance adiponectin high fat diet high-fat TNFα | ||
| 100030 | Endothelial Lipase Polyclonal Antibody | - |
|
2004-01-05 | 29.296406543732 | endothelial-lipase-polyclonal-antibody | EDL; EL | antibodies antisera antiserum western blots blotting wb icc immunocytochemistry atherosclerosis special:month specialdiscount:15 specialstart:2008-03-01 specialend:2008-03-31 immunoblotting IHC immunohistochemistry | |||
| 583151 | Endothelin EIA Kit | - |
|
154.873232044198 | endothelin-eia-kit | ET EIA Kit; Endothelin ELISA Kit | atherosclerosis ET-1 vascular vasoconstriction measures kits eias enzyme immunoassays ELISAs endocrinology assays | ||||
| 60880 | eNOS (bovine recombinant) | - | cell lysate 100,000 x g supernatant | 61.960022099447 | enos-bovine-recombinant | ecNOS; NOS III; Endothelial Nitric Oxide Synthase | endothelial enzymes nitric oxide synthases cow atherosclerosis | ||||
| 360880 | eNOS Electrophoresis Standard | - | >95% | 5.424005524861 | enos-electrophoresis-standard | ecNOS; NOS III; Endothelial Nitric Oxide Synthase | standards western blots blotting gels staining WB synthases polyacrylamide NOS-3 atherosclerosis | ||||
| 160880 | eNOS Polyclonal Antiserum | - | 20.850870165746 | enos-polyclonal-antiserum | ecNOS; NOS III; Endothelial Nitric Oxide Synthase | synthases Western blots cells EDRF vasculature antisera blotting WB antibodies antiserum atherosclerosis immunoblotting IP immunoprecipitation | |||||
| 10477 | EP2 Receptor Polyclonal PE Antibody New | - |
|
2010-07-07 | 300.437306629834 | ep2-receptor-polyclonal-pe-antibody | Prostaglandin E2 Receptor 2; PGE2 Receptor 2 | R-phycoerythrin immunofluorescent FL-2 FL2 FL 2 channels G-protein coupled G protein flow cytometry FC immunofluorescence IF EP1 EP2 EP3 EP4 cAMP smooth muscles mRNA tissues lungs placenta placenta spleen intestines kidneys sensory neurons | |||
| 10009547 | FABP1 (human recombinant) Exclusive | - | >90% | ✓ | 2007-09-04 | 39.901411909146 | fabp1-human-recombinant | Liver-FABP; L-FABP; Fatty Acid Binding Protein | proteins metabolism cellular membranes FABP-1 FABPs fatty acids bladders carcinoma renal failure LFABP livers kidneys atherosclerosis endocrinology | ||
| 10005200 | FABP1 (rat recombinant) | - | >95% | 2005-07-29 | 22.467799263351 | fabp1-rat-recombinant | Liver-Fatty Acid Binding Protein; Fatty Acid Binding Protein 1; Liver-FABP; L-FABP | protein-only proteins cytosolic fatty acids antiparallel .beta. strands barrel expression hepatoblastoma hepatocellular carcinomas tumors markers liver kidney injury fluorescence displacement assay fluorescent analogue 11-(Dansylamino)undecanoic DAUDA arachidonic oleic pocket atherosclerosis endocrinology | |||
| 10010019 | FABP2 Polyclonal Antibody | - |
|
2007-10-02 | 16.696056098597 | fabp2-polyclonal-antibody | Intestinal Fatty Acid Binding Protein; Fatty Acid Binding Protein 2; I-FABP | WB western blots fatty acids FABPs lipophilic ligands metabolism polymorphism FABP2 IFABP obesity diabetes antibodies antiserum diabetic antisera atherosclerosis endocrinology blotting immunoblotting | |||
| 10007938 | FABP2 (rat recombinant) | - | >95% | 2005-12-16 | 22.467799263351 | fabp2-rat-recombinant | Fatty Acid Binding Protein 2; I-FABP; Intestinal-FABP | protein-only fatty acids binding proteins high affinity constants small endogenous exogenous lipophilic ligands uptake metabolism cellular membranes levels intracellular trafficking substrates modulation enzymes lipid metabolic pathways cells growth differentiation antiparallel .beta. strands barrel cytosolic tissues biomarker myocardial injury infarction atherosclerosis endocrinology | |||
| 10007432 | FABP3 (human recombinant) | - | >95% |
|
2005-07-27 | 84.961737820190 | fabp3-human-recombinant | Heart-FABP; Fatty Acid Binding Protein-3; H-FABP | protein-only fatty acids binding proteins high affinity constants small endogenous exogenous lipophilic ligands uptake metabolism cellular membranes levels intracellular trafficking substrates modulation enzymes lipid metabolic pathways cells growth differentiation antiparallel .beta. strands barrel cytosolic tissues biomarker myocardial injury infarction atherosclerosis endocrinology | ||
| 10233 | FABP3 Monoclonal Antibody (Clone CC68) | - | 2009-03-20 | 21.366427255984 | fabp3-monoclonal-antibody-clone-cc68 | Cardiac FABP; Fatty acid binding protein 3; Heart fatty acid binding protein; H-FABP | antibody antisera antiserum antibodies wb western blots immunoblotting small endogenous exogenous lipophilic ligands uptake metabolism cellular membranes levels intracellular trafficking substrates modulation enzymes lipid metabolic pathways cells growth differentiation antiparallel .beta. strands barrel cytosolic tissues biomarker myocardial injury infarction atherosclerosis endocrinology blotting | ||||
| 10007614 | FABP4 (human) EIA Kit | - |
|
2006-10-13 | 21.193254645906 | fabp4-human-eia-kit | Fatty Acid Binding Protein 4 (human) EIA Kit; Adipocyte-FABP (human) EIA Kit; A-FABP (human) ELISA Kit | 10009284 SPI-BIO spibio ELISA immunoassay enzyme A05181 FABP4 fatty acid binding protein adipocytes aP2 atherosclerosis endocrinology assays | |||
| 10009549 | FABP4 (human recombinant) | - | >90% | 2007-06-15 | 41.334816675037 | fabp4-human-recombinant | A-FABP; ALBP; Adipocyte-FABP; Fatty Acid Binding Protein 4; aP2; Adipocyte Fatty Acid Binding Protein | cytosolic fatty acids lipophilic ligands tissues uptake metabolism intracellular trafficking lipid FABP-4 metabolic pathways cell growth differentiation bidirectional flux insulin epinephrine adipocytes atherosclerosis endocrinology | |||
| 10010463 | FABP4 (human recombinant) Western Ready Control | - | 2007-10-23 | 10.947190213101 | fabp4-human-recombinant-western-ready-control | Fatty Acid Binding Protein 4; Adipocyte-FABP; ALBP; FABP4; A-FABP | fatty acids proteins western blots blotting WB binding proteins adipocytes atherosclerosis endocrinology immunoblotting | ||||
| 10010231 | FABP4 Inhibitor/Ligand Screening Assay Kit | - |
|
2007-11-01 | 43.764596685083 | fabp4-inhibitor-ligand-screening-assay-kit | aP2; Adipocyte Fatty Acid Binding Protein; A-FABP; Fatty Acid Binding Protein 4 | fabps kits atherosclerosis assays fatty acid binding protein adipocytes aP2 cytosolic lipophilic ligands uptake metabolisms cellular membranes intracellular trafficking cells growth differentiation PPARg PPARgamma PPAR.gamma. peroxisomes proliferator-activated receptors agonists insulin genes deletion mice mouse murine chronic metabolic diseases diabetes atherosclerosis fluorescence fluorescent fluorometric endocrinology | |||
| 10005191 | FABP4 (murine recombinant) | - | >95% | 2005-07-27 | 50.747067573310 | fabp4-murine-recombinant | Adipocyte-FABP; ALBP; Fatty Acid Binding Protein 4; A-FABP | protein-only protein-4 endogenous exogenous lipophilic ligands uptake metabolism intracellular trafficking lipid metabolic pathways modulation cell growth differentiation antiparallel .beta. strands barrel fat cells specific facilitate bidirectional flux insulin epinephrine proteins recombinant binding adipocytes fatty acids agonists insulin hyperinsulinemia deficiency afabp adipocytes atherosclerosis endocrinology | |||
| 10009676 | FABP4 (murine recombinant) Western Ready Control | - | 2007-04-30 | 16.605474635861 | fabp4-murine-recombinant-western-ready-control | ALBP; Fatty Acid Binding Protein 4; Adipocyte-FABP; A-FABP | fatty acids proteins western blots blotting WB binding proteins adipocytes atherosclerosis | ||||
| 10004944 | FABP4 Polyclonal Antibody | - |
|
2004-11-05 | 21.790949271722 | fabp4-polyclonal-antibody | Fatty Acid Binding Protein 4; aP2; A-FABP; ALBP | atherosclerosis adipocytes macrophages 3T3-L1 fatty acids PPAR.gamma. PPARgamma agonists insulin WB western blots blotting ICC immunocytochemistry hyperinsulinemia deficiency antibodies antiserum antisera endocrinology immunoblotting | |||
| 10010364 | FABP5 (human recombinant) | - | >95% | 2007-08-08 | 54.029042357274 | fabp5-human-recombinant | Keratinocyte FABP; Psoriasis-Associated FABP; Fatty Acid Binding Protein 5; Epidermal-FABP; E-FABP; DA11 FABP | proteins lipophilic ligands uptake metabolism cellular membranes FABP-5 FABPs cytosolic fatty acids bladders carcinoma prostates atherosclerosis endocrinology | |||
| 10007433 | FABP5 (murine recombinant) | - | >95% | 2005-07-29 | 26.874458563536 | fabp5-murine-recombinant | Epidermal-FABP; Fatty Acid Binding Protein 5; E-FABP | protein-only proteins cytosolic acids lipophilic ligands uptake metabolism cellular membranes intracellular trafficking modulation enzymes lipids metabolic pathways cells growth differentiation antiparallel B .beta. strands barrel prostates bladder carcinomas atherosclerosis endocrinology neurochemistry | |||
| 10009551 | FABP7 (human recombinant) | - | >90% | 2007-06-27 | 16.522061198469 | fabp7-human-recombinant | B-FABP; Brain-FABP; Fatty Acid Binding Protein 7 | cytosolic FABPs amino acids lipophilic ligands tissues metabolism pathways docosahexanoic fatty binding proteins atherosclerosis endocrinology | |||
| 10010501 | Farnesyl Thiosalicylic Acid | 162520-00-5 | ≥96% |
|
2008-06-02 | 21.547403314917 | farnesyl-thiosalicylic-acid | Salirasib; FTS | ras inhibitors inhibition inhibits cancer anti-cancer anticancer prenylation farnesylation signal transduction oncogene atherosclerosis farnesylthiosalicylic acid | ||
| 10005368 | Fenofibrate | 49562-28-9 | >98% |
|
2004-09-15 | 34.996955801105 | fenofibrate | PPAR.alpha. PPARalpha ligands selective peroxisome proliferator-activated receptors nuclear fibrate agonists lipids dyslipidemia fatty acids b-oxidation beta-oxidation .beta.-oxidation hypolipidemic drugs cardiovascular diseases atherosclerosis endocrinology | |||
| 70440 | Filipin III | 480-49-9 | >85% |
|
44.479510655091 | filipin-iii | Filipin-3 Filipin-III Cholesterol fluorescent fluorescence atherosclerosis filipin 111 | ||||
| 10010337 | Fluvastatin (sodium salt) | 93957-55-2 | >98% |
|
2008-02-27 | 10.747123125493 | fluvastatin-sodium-salt | atherosclerosis HMG-CoA reductases LDL LDL-c HDL HDL-c statin cholesterol heart disease CVD inhibitors inhibits inhibition | |||
| 10039 | FR122047 (hydrate) | - | >98% |
|
14.973966469803 | fr122047-hydrate | 130717-51-0 FR-122047 cyclooxygenases COX-1 inhibitors hydrates hydrochlorides COX1 PGHS1 PGHS-1 prostaglandin synthases inhibition inhibits selective selectivity platelet aggregation antiinflammatory atherosclerosis | ||||
| 70540 | Furegrelate (sodium salt) | 85666-17-7 | >99% |
|
5.919889502762 | furegrelate-sodium-salt | U-63557A | thromboxanes synthases inhibitors inhibits inhibition salts atherosclerosis | |||
| 10006798 | GW 0742 | 317318-84-6 | >98% |
|
2007-07-25 | 48.434872928176 | gw-0742 | PPAR PPAR.beta. PPAR.delta. peroxisome proliferator activated receptor neurotoxicity agonists neuroprotection toxicity apoptosis lipids metabolism atherosclerosis endocrinology GW0742 GW-0742 | |||
| 10009880 | GW 590735 Exclusive | 622402-22-6 | >98% |
|
✓ | 2007-06-18 | 4.187845303867 | gw-590735 | PPAR PPAR.alpha. PPAR.BETA. PPAR.gamma. PPAR.delta. receptor transcription factors lipidtriglyceride TG lipoprotein VLDL ApoCIII ApoA1 HDL atherosclerosis endocrinology | ||
| 10008613 | GW 7647 | 265129-71-3 | >98% |
|
2006-08-02 | 34.642707182320 | gw-7647 | PPAR.alpha. peroxisome proliferator-activated receptor triglycerides lipid homeostasis transcription factor fibrate atherosclerosis endocrinology GW7647 | |||
| 10011211 | GW 9578 Exclusive | 247923-29-1 | >98% |
|
✓ | 2008-05-23 | 41.644871923656 | gw-9578 | atherosclerosis PPAR.alpha. PPARalpha PPARa LDLs lipids nuclear receptors fibrates diabetes obesity peroxisome perliforetior-activated | ||
| 70785 | GW 9662 | 22978-25-2 | ≥98% |
|
146.139404542664 | gw-9662 | GW-9662 GW9662 ligands ppar.gamma. ppargamma peroxisome proliferator-activated nuclear endocrinology receptors antagonists atherosclerosis | ||||
| 9000497 |
GW 9662- |
- | ≥99% deuterated product |
|
✓ | 2009-09-30 | 78.169165131982 | gw-9662-d5 | deuterateds deuterium GC/MS GC-MS LC/MS LC-MS mass spectrometry GW-9662 GW9662 ligands ppar.gamma. γ ppargamma peroxisome proliferator-activated nuclear endocrinology receptors antagonists atherosclerosis TZDs thiaolidinediones PPARs | ||
| 10010559 |
HA- |
203911-27-7 | ≥98% |
|
2008-09-03 | 30.874281767956 | ha-1077-hydrochloride | Eril; Fasudil (hydrochloride) | protein kinase inhibitors inhibits inhibition ROCK-II ROCKII PRK2 MSK1 MAPKAP-K1b vasodilation hypertension diabetes renal nephropathy cancers | ||
| 10006084 | Hesperetin | 520-33-2 | >98% |
|
2005-02-16 | 17.510257826887 | hesperetin | hesperitin hesperidin atherosclerosis citrus nutraceuticals flavonoids flavanoids hypocholesterolemic ACAT2 ACAT-2 mRNA transcription inhibits inhibition inhibitors ApoB proteins histamines azelastine atherosclerosis | |||
| 13354 | Hexacosanoic Acid | 506-46-7 | ≥98% |
|
2009-07-24 | 0.269999999999 | hexacosanoic-acid | Cerotic Acid; NSC 4205; Ceric Acid | fatty acids very long chain very-long-chain peroxisomes peroxisomals disorders adrenoleukodystrophy atherosclerosis metabolic syndromes red blood cells plasma ceratinic acids cerinic cerylic n-hexacosanoic | ||
| 10006371 | Hormone Sensitive Lipase Polyclonal Antibody | - | 2005-06-22 | 11.239911602210 | hormone-sensitive-lipase-polyclonal-antibody | HSL | proteins antibodies antisera antiserum WB western blots blotting IHC immunohistochemistry ICC immunocytochemistry catalyses hydrolysis of tri- di- monoacylglycerols cholesterol esters mobilizes fatty acids primary source energy mammals enzyme expressed adipose tissues stearidonic steroidgenesis spermatogenesis foam cell formation atherosclerosis diabetic pathology human cDNA isoforms testis mRNA mouse murine macrophages testicular ram seminal vesicles triacylglycerols diacylglycerols atherosclerosis | ||||
| 18215 | Iloprost | 78919-13-8 | >97% |
|
159.693819060773 | iloprost | Ciloprost | agonists IP receptors vasodilator hypostensive atherosclerosis antiduretic hypertension analogs PGI2 prostaglandins prostacyclin selective selectivity pharma:21 | |||
| 10005518 | IP Receptor (human) Polyclonal Antibody | - | 2004-10-21 | 21.225132305903 | ip-receptor-human-polyclonal-antibody | Prostaglandin I2 Receptor; Prostacyclin Receptor; PGI2 Receptor | antibodies antisera antiserum western blots blotting wb prostacyclins rat PGI2 prostaglandins receptors immunoblotting atherosclerosis | ||||
| 160070 | IP Receptor (murine) Polyclonal Antibody | - |
|
2004-05-25 | 21.991111878453 | ip-receptor-murine-polyclonal-antibody | PGI2 Receptor; Prostacyclin Receptor; Prostaglandin I2 Receptor | antibodies antisera antiserum western blots blotting wb prostacyclins rat PGI2 prostaglandins receptors atherosclerosis neurochemistry immunoblotting | |||
| 19021 |
I- |
133538-58-6 | >98% |
|
6.256737338858 | i-sap | Iodophenyl sulfonyl amino pinane Thromboxane A2; Iodophenyl sulfonyl amino pinane TXA2 | thromboxanes ISAP pinane analogs agtagonists TP receptors atherosclerosis | |||
| 10011054 | KB2115 Exclusive | 355129-15-6 | ≥98% |
|
✓ | 2008-06-10 | 6.742541436464 | kb2115 | thyroid hormones dyslipidemia LDL cholesterol statins cardiovascular disease atherosclerosis obesity | ||
| 62935 |
KDdiA- |
439904-34-4 | >98% |
|
✓ | 2005-09-09 | 10.425159371015 | kddia-pc | CD36 ligands oxidized oxLDL low density lipoproteins particles cytotoxics pro-atherogenic phosphatidylcholines species short-chain fatty acids sn-2 scavengers receptors structural determinants binding affinity atherosclerosis | ||
| 62945 |
KOdiA- |
439904-33-3 | >98% |
|
✓ | 2004-01-28 | 42.215521178637 | kodia-pc | oxidative injury lipids oxLDL oxidized low-density lipoproteins phosphatidylcholines CD36 CD-36 scavengers receptors binding atherosclerosis | ||
| 10009324 | LCAT Blocking Peptide | - | 2007-01-03 | 22.862486187845 | lcat-blocking-peptide | Lecithin:Cholesterol Acyltransferase; Phosphatidylcholine-Sterol-O-Acyltransferase | antibodies western blotting blots signaling signalling WB controls peptides proteins cholesterols acetyltransferases phospholipases catalyzes fatty acids transfers sn-2 phosphatidylcholines enzymes esters high-density lipoproteins HDL cells blood-plasma tissues ovary | ||||
| 10009323 | LCAT Polyclonal Antibody | - |
|
2007-01-03 | 23.646163290361 | lcat-polyclonal-antibody | Lecithin:Cholesterol Acyltransferase; Phosphatidylcholine-Sterol O-Acyltransferase | proteins diseases antibodies antisera antiserum WB western blots blotting cholesterols acetyltransferases phospholipases catalyzes fatty acids transfers sn-2 phosphatidylcholines enzymes esters high-density lipoproteins HDL cells blood-plasma tissues ovary atherosclerosis immunoblotting | |||
| 10007672 | LDL Receptor Blocking Peptide | - | 2007-05-03 | 40.481491712707 | ldl-receptor-blocking-peptide | Low-density Lipoprotein Receptor Blocking peptide; LDLR Blocking Peptide | proteins diseases WB western blots blotting ICC immunocytochemistry cholesterols cells membranes lipoproteins low density receptors LDLRs glycoproteins blood regulates plasma ligands binding domains EGF O-link sugars membrane-spanning regions cytoplasmic livers hormonal controls mutations familial hypercholesterolemia atherosclerosis mouse murine N- SDS-PAGE unglycosylated HepG2 RAW 264.7 | ||||
| 10007665 | LDL Receptor Polyclonal Antibody | - |
|
2006-02-15 | 55.282596685083 | ldl-receptor-polyclonal-antibody | LDLR Polyclonal Antibody | proteins diseases antibodies antisera antiserum WB western blots blotting ICC immunocytochemistry cholesterols cells membranes lipoproteins low density receptors LDLRs glycoproteins blood regulates plasma ligands binding domains EGF O-link sugars membrane-spanning regions cytoplasmic tails livers hormonal controls in vivo vitro mutations familial hypercholesterolemia atherosclerosis mouse murine N- SDS-PAGE unglycosylated HepG2 RAW 264.7 cell-based assay cell based assay cba immunoblotting | |||
| 10011125 |
LDL Uptake Cell- |
- |
|
2008-04-29 | 28.423385951066 | ldl-uptake-cell-based-assay-kit | Low-Density Lipoprotein Uptake | atherosclerosis cholestrols plasmas blood coronary heart diseases low-density lipoproteins kits assays assaying tools uptakes regulation | |||
| 10007817 | Leukotriene A4 Hydrolase (human recombinant) | - | >90% | 2005-12-14 | 457.308839779005 | leukotriene-a4-hydrolase-human-recombinant | LTA4H | leukotrienes bifunctional zinc metalloenzymes converts LTB4 neutrophils chemoattractants hydrolases activity anion-dependent aminopeptidases drugs leukocytes infiltration inflammation E. coli epoxides atherosclerosis | |||
| 20110 | Leukotriene B4 | 71160-24-2 | ≥97% |
|
298.663421731123 | leukotriene-b4 | LTB4 | leukotrienes LTB4 inflammation chemotaxis atherosclerosis | |||
| 320110 |
Leukotriene B4- |
- | ≥99% deuterated product |
|
186.054696132596 | leukotriene-b4-d4 | LTB4-d4 | GC/MS LTB4-d4 deuterium internal standards isotopes leukotrienes GC-MS mass spectrometry LC/MS LC-MS deuterated spectroscopy atherosclerosis mass spectrometry | |||
| 520111 | Leukotriene B4 EIA Kit | - |
|
899.897139349294 | leukotriene-b4-eia-kit | Leukotriene B4 ELISA Kit | solid plates neutrophils 5-LOs 5-lipoxygenases LTB4 measures kits atherosclerosis eias enzyme immunoassays ELISAs leukotrienes assays | ||||
| 10007240 | Leukotriene B4 Lipid Maps MS Standard | 71160-24-2 | ≥97% |
|
2009-01-14 | 37.749828729282 | leukotriene-b4-lipid-maps-ms-standard | LTB4 | leukotrienes LTB4 inflammation chemotaxis atherosclerosis LTs MS mass spectrometry standards | ||
| 520411 | Leukotriene E4 EIA Kit | - |
|
154.831112865036 | leukotriene-e4-eia-kit | Leukotriene E4 ELISA Kit | kitrecommendation:cyslt allergy cys-LTs cysteinyl-leukotrienes atherosclerosis neutrophils LTE4 measures kits eias enzyme immunoassays ELISAs asthma cysteinyl-LTs peptido-LTs peptido-leukotrienes assays | ||||
| 89430 | Linolein Hydroperoxides | - | >98% (A mixture of 132 isomers) |
|
4.024530386740 | linolein-hydroperoxides | trilinoleins autoxidation atherosclerosis isomers hydroperoxy fatty acids | ||||
| 705002 | Lipid Hydroperoxide (LPO) Assay Kit | - |
|
332.811721915285 | lipid-hydroperoxide-lpo-assay-kit | lipids peroxidation oxidative injury inflammation free radicals colorimetric hydroperoxides stress atherosclerosis assays | |||||
| 10011119 | Liver X Receptor β Transcription Factor Assay Kit | - |
|
2008-09-05 | 26.136344383057 | liver-x-receptor-transcription-factor-assay-kit | LXRβ Transcription Factor Assay Kit | tf LXRbeta LXRb LXR.beta. LXRalpha LXRa LXR.alpha. LXRα LXRs atherosclerosis ligand-activated nuclear receptors cholesterols fatty acids glucose homeostastis NR1H2 tissues in vivo DNA sequences LXREs heterodimers retinoic X RXR target genes LXR/RXR complex permissive endogenous steroids vitamin D thyroid hormones oxidized oxysterols synthetic T0901317 GW3965 type 2 diabetes cardiovascular diseases obesity syndrome X assays | |||
| 10010338 | Lovastatin | 75330-75-5 | >98% |
|
2008-03-03 | 16.259664258393 | lovastatin | LDL-c cholesterol HMG-CoA reductase HMGCoA statins heart diseases CVD atherosclerosis HDL-c NF-kB NF-.kappa.B TNF-.alpha. apoptosis anti-cancer mevacor Altocor mevinolin inhibits inhibitors inhibition | |||
| 10010339 | Lovastatin Hydroxy Acid (sodium salt) Exclusive | - | >98% |
|
✓ | 2008-03-04 | 20.171491712707 | lovastatin-hydroxy-acid-sodium-salt | atherosclerosis LDL cholesterol HMG-CoA reductase statin heart disease CVD LDL-c HDL HDL-c inhibitors inhibits inhibition | ||
| 10010971 |
Luminex® 11- |
- |
|
2008-01-24 | 52.225662983425 | luminex-11-dehydro-thromboxane-b2-kit | Luminex® 11-dehydro TXB2 Kit | thromboxanes thromboxane A2 TXA2 metabolites urine in vivo measures kits luminex xMAP beads assays | |||
| 10010497 | Manumycin A | 52665-74-4 | ≥98% |
|
2008-06-25 | 13.340000000000 | manumycin-a | UCF 1C; NSC 622141 | farnesyltransferase inhibitors inhibits inhibition cancer antitumor anti-tumor signal transduction Ras farnesylation NF-.kappa.B NF-kB NF-kappaB | ||
| 90290 | MEDICA 16 | 87272-20-6 | >98% |
|
41.231132596685 | medica-16 | hypolipidemic antidiabetogenic analogs fatty acids diabetes antidiabetic b,b'-hexadecanedioic nuclear receptors beta,beta-hexadecanedioic .beta.,.beta.'-hexadecanedioic VLDL decrease atherosclerosis | ||||
| 600160 | Methionine Sulfoxide Immunoblotting Kit | - |
|
2009-12-17 | 143.321805433729 | methionine-sulfoxide-immunoblotting-kit | MetO Immunoblotting Kit | proteins sulfoxides oxidative modifications residues MSRs reactive oxygen species ROSs methionines oxidations reductases sulfones phagocytosis phagocytotic mitochondrias mitochondrial respirations sulfoxidations age-related diseases cellular cells IgG-containing sera Alzheimer's diseases immunoblots immunoblotting western blots blotting kits assays measures measurements detection tissues lysates semi-pure purified reducing non-reducing sample buffers SDS-PAGE rabbit serums immunizations oxidized corn MetO-DZS18 | |||
| 10010340 | Mevastatin | 73573-88-3 | ≥98% |
|
2008-07-16 | 13.222276243094 | mevastatin | Statin I; NSC 281245; L 637312; Compactin; ML 236B; CS 500 | atherosclerosis cholesterol HMG-CoA reductases statins heart diseases CVD LDL-c LDLc HDL-c HDLc TNF-.alpha. TNF-a TNF-alpha NF-kb NF-.kappa.B NF-kappaB apoptosis cancers cardiovascular TNF.alpha. inhibtis inhibitor inhibition HMGCoA pythium ultimum | ||
| 10009835 | MK 0524 | 571170-77-9 | >98% |
|
2008-05-06 | 62.451239147592 | mk-0524 | Laropiprant | antagonist PGD2 allergy asthma DP1 niacin vasodilations flushing dyslipidemia receptors atherosclerosis hypertension inflammation mk0524 | ||
| 10006438 | Myeloperoxidase Chlorination Assay Kit | - |
|
2009-04-14 | 29.683701657458 | myeloperoxidase-chlorination-assay-kit | MPO Chlorination Assay Kit | heme peroxidases azurephilic granules leukocytes neutrophils monocytes tissues macrophages chlorides hydrogen peroxides H2O2 Cl- hypochlorous acids acute chronic vascular inflammatory diseases cardiac therapeutics cycles fluorescence fluorescent assays kits measures measurement crude cells lysates purified enzymes APF 2-[6-(4-aminophenoxy)-3-oxo3H-xanthen-9-yl]-benzoic acid hypochlorite -OCl | |||
| 10012600 | Myricetin | 529-44-2 | >98% |
|
2009-02-20 | 13.802596685083 | myricetin | NSC 407290; Cannabiscetin | flavonoid antioxidant oxLDL CD36 atherosclerosis cancers JAK1 STAT3 MEK1 | ||
| 63150 | Myriocin | 35891-70-4 | >98% |
|
2007-05-03 | 66.629095303867 | myriocin | Thermozymocidin; ISP-1 | serine palmitoyltransferase inhibitors sphingolipids antibiotic immunosuppressants inhibition inhibited atherosclerosis | ||
| 13055 | Naphthofluorescein | 61419-02-1 | ≥98% |
|
2009-03-20 | 2.733129439620 | naphthofluorescein | CCG 8295 | furin matrix metalloproteinase MTA-MMP MMP2 motility invasion cancer metastasis MMP inhibitors naphthafluorescein | ||
| 80230 |
NG,NG- |
220805-22-1 | >98% |
|
14.595124309392 | ng-ng-dimethyl-l-arginine-hydrochloride | ADMA (hydrochloride) | endogenous nitric oxide synthase inhibitors NOS renal failure preeclampsia inhibits inhibition asymmetric dimethylarginine hypercholesterolemia atherosclerosis muscular dystrophy | |||
| 189542 | Nitrotyrosine Monoclonal Antibody | - |
|
49.696519337016 | nitrotyrosine-monoclonal-antibody | peroxynitrite nitric oxide superoxide oxidative injury stress Alzheimer's diseases antibodies NO western blots blotting WB nitration proteins antisera antiserum IHC immunohistochemistry immunoprecipitation IP atherosclerosis immunoblotting EIA enzyme immunoassays | |||||
| 10009661 |
N- |
- | >95% |
|
2008-04-23 | 0E-12 | n-octadecyl-n-propyl-sulfamide | PPAR.alpha. PPARa PPARalpha OEA satiety obesity metabolism food intake triglyceride lipids activators appetite suppression | |||
| 10010411 |
NS- |
475086-01-2 | >98% |
|
2008-04-09 | 56.267127071823 | ns-304 | ACT-293987; Selexipag | prostaglandins PGI2 IP receptors inflammation MRE-269 agonists vasodilator hypotensive vascular diseases atherosclerosis hypertension analogs potent selective PGs | ||
| 10006782 |
Oleic Acid- |
140112-65-8 | >98% |
|
2005-05-18 | 1.587292817679 | oleic-acid-2-6-diisopropylanilide | HDL LDL cholesterols ACAT inhibitors ODA acylCoA:cholesterol acyltransferase intracellular cholesteryl esters synthases dietary inhibits low-density liproteins high-density inhibition atherosclerosis | |||
| 10006529 | Oleyl Anilide | 5429-85-6 | >95% |
|
2005-05-18 | 3.902375690607 | oleyl-anilide | OA; Oleic Acid Anilide | HDL LDL cholesterols ACAT inhibitors ODA acylCoA:cholesterol acyltransferase intracellular cholesteryl esters synthases dietary inhibits glycerides dioleoyl phenylamino propane 1,2-diols eosinophilia excessive T cell activation acute pulmonary inflammatory reactions TOS toxic oil syndrome aniline-denatured cooking oils interleukins atherosclerosis | ||
| 600240 | Orexin 1 Receptor STEP Reporter Assay Kit (Luminescence) New | - |
|
2010-03-31 | 0E-12 | orexin-1-receptor-step-reporter-assay-kit-luminescence | OX1R | hypercretins 1 orexins 2 A orexin-2 systems regulates regulator sleep wake cycles feeding cardiovascular autonomic hypothalamic neuropeptides Orexins A Orexins B gut hormones secretions hypothalamus midbrains brainstems G protein-coupled receptors GPCRs orexin-1 OX1R orexin-2 OX2R orexin-A orexin-B sleep disorders narcolepsy humans animals rodents energy homeostasis pain stress antagonists drugs addictions withdrawals therapeutics obesity Surface transfection expression protocols solid phase transient transfection technology originus patents USPT US6897067 US6902933 US7056741 US 6897067 6902933 7056741 DNA deoxyribonucleases adherent cells receptor-mediated luminescent secretory alkaline phosphatases SEAP signal transduction cascades culture medium luminescence-based high throughput screening screens agonists | |||
| 600250 | Orexin 2 Receptor STEP Reporter Assay Kit (Luminescence) New | - |
|
2010-03-31 | 0E-12 | orexin-2-receptor-step-reporter-assay-kit-luminescence | OX2R | hypercretins 1 orexin 2 systems regulates regulator sleep wake cycles feeding cardiovascular autonomic hypothalamic neuropeptides Orexins A Orexins B gut hormones secretions hypothalamus midbrains brainstems G protein-coupled receptors GPCRs orexin-1 OX1R orexin-2 OX2R orexin-A orexin-B sleep disorders narcolepsy humans animals rodents energy homeostasis pain stress antagonists drugs addictions withdrawals therapeutics obesity Surface transfection and expression protocols solid phase transient transfection technology originus patents USPT US6897067 US6902933 US7056741 US 6897067 6902933 7056741 DNA deoxyribonucleases adherent cells receptor-mediated luminescent secretory alkaline phosphatases SEAP signal transduction cascades culture medium luminescence-based high throughput screening screens agonists | |||
| 34004 | Oxidized Lipid HPLC Mixture | - | >98% for each compound | 12.285917740945 | oxidized-lipid-hplc-mixture | ROS peroxidation LDL atherosclerosis autoxidation reactive oxygen species (+/-)9-HODEs (+/-)13-HODEs esters (+/-)15-HETEs (+/-)-HODEs (+/-)-HETEs hydroxy fatty acids racemic (+/-)HODEs (+/-)HETEs cholesteryl esters | |||||
| 10007893 |
oxLDL- |
- | 2006-01-24 | 58.792928176796 | oxldl-2gpi-human-elisa-kit | Oxidized low-density lipoprotein-β2 Glycoprotein I (human) EIA kit | ox-ldl ox ldl eia atherosclerosis enyzme immunoassay territory:americas assays | ||||
| 70515 | Ozagrel | 82571-53-7 | >98% |
|
3.896095764272 | ozagrel | OKY-046 | thromboxanes synthases inhibitors inhibits imidizoles TXAs antihypertensive inhibition atherosclerosis | |||
| 10011301 | p38 MAPK Monoclonal Antibody (Clone 9F12) | - |
|
2008-05-22 | 2.615138121547 | p38-mapk-monoclonal-antibody-clone-9f12 | p38 Mitogen-activated Protein Kinase; p38 MAPKα | serine threonine serine-threonine cell cycles development apotosis kinases stress signals cytokines gene expression western blots immunoblotting immunocytochemisty ICC WB flow cytometry signal transduction signalling signaling blotting FC | |||
| 10010374 |
p38 MAPK (Phospho- |
- |
|
2007-09-17 | 3.287292817679 | p38-mapk-phospho-thr180-tyr182-cell-based-phosphorylation-translocation-assay-kit | phosphorylation kits assays enzymes diseases asthma autoimmunity stress response nervous system fluorescence fluorescent fluorometric | ||||
| 760901 | PAF Acetylhydrolase Assay Kit | - |
|
102.313073204420 | paf-acetylhydrolase-assay-kit | PAF-AH; Lp-PLA2 | PAF-AH colorimetric phospholipids atherosclerosis cytosolic extracellular platelet-activating factors PAFs enzymes analysistools:cytpafah analysistools:expafah assays paf elisa kit | ||||
| 160603 | PAF Acetylhydrolase (human) Polyclonal Antibody | - |
|
12.481491712707 | paf-acetylhydrolase-human-polyclonal-antibody | Platelet-activating Factor Receptor Acetylhydrolase; PAF-AH; Lp-PLA2 | atherosclerosis platelet-activating factors Western blots asthma inflammation preeclampsia antisera PAFs WB antibodies antiserum blotting immunoblotting | ||||
| 10010081 | PAF Acetylhydrolase (human) Western Ready Control | - | 2007-05-30 | 9.223024861879 | paf-acetylhydrolase-human-western-ready-control | PAF-AH; Lp-PLA2; Platelet-activating Factor Acetylhydrolase | western blotting WB atherosclerosis factors asthma inflammation PAFs | ||||
| 10004380 | PAF Acetylhydrolase Inhibitor Screening Assay Kit | - |
|
2004-03-29 | 48.158994475137 | paf-acetylhydrolase-inhibitor-screening-assay-kit | PAF-AH Inhibitor Screening Assay Kit; Lp-PLA2 Inhibitor Screening Assay Kit | platelet-activating factors hypotension inflammations allergys PAFAH atherosclerosis heart diseases measures kits inhibitors PAFs assays paf elisa kit | |||
| 60900 |
PAF C- |
74389-68-7 | >98% |
|
15.989359116022 | paf-c-16 | Platelet-activating Factor C-16 | PAFs platelet-activating factors atherosclerosis | |||
| 360900 |
PAF C- |
- | ≥99% deuterated product |
|
17.036574585636 | paf-c-16-d4 | Platelet-activating Factor C-16-d4 | PAFs deuterium GC/MS internal isotopes deuterated PAF-C-16-d4 standards GC-MS LC/MS LC-MS mass spectrometry platelet-activating factors atherosclerosis | |||
| 60910 |
PAF C- |
74389-69-8 | >97% |
|
8.819815837936 | paf-c-18 | PAFs platelet-activating factors atherosclerosis | ||||
| 160600 | PAF Receptor (human) Monoclonal Antibody (11A4, Clone 21) | - | 24.093093922652 | paf-receptor-human-monoclonal-antibody-11a4-clone-21 | Platelet-activating Factor Receptor | platelet-activating factors antibodies PAFs ICC immunocytochemistry antisera antiserum flow cytometry FACS receptors atherosclerosis PAFR FC | |||||
| 160602 | PAF Receptor (human) Polyclonal Antibody | - |
|
27.570110497238 | paf-receptor-human-polyclonal-antibody | Platelet-activating Factor Receptor | platelet-activating factors antisera PAFs antiserum antibodies flow cytometry facs immunocytochemistry icc western blots blotting wb atherosclerosis PAFR FC immunoblotting | ||||
| 10009871 | Palmitoleic Acid | 373-49-9 | ≥99% |
|
2008-08-25 | 30.068784530387 | palmitoleic-acid | Palmitoleate; cis-Palmitoleic Acid; 9-cis-Hexadecenoic Acid; n-7 Palmitoleate | monounsaturated fatty acids LDL HDL cholesterol diet | ||
| 62924 |
PAz- |
117746-89-1 | >98% |
|
9.363931860036 | paz-pc | Azelaoyl PC; 1-Palmitoyl-2-Azelaoyl PC | PPAR.gamma. PPARgamma receptors thiazolidinediones binding sites atherosclerosis | |||
| 10007185 | PCSK9 (human) Polyclonal Antibody | - |
|
2005-11-30 | 23.462864204711 | pcsk9-human-polyclonal-antibody | Proprotein Convertase Subtilisin Kexin 9; NARC-1 | atherosclerosis proteins diseases antibodies antisera antiserum WB western blots blotting ICC immunocytochemistry serines proteases family lipoproteins subtilisin metabolisms mutations genes autosomal doimant dominance hypercholesterolemia low density LDLs overexpressions plasmas total cholesterols livers kidneys lungs spleens jejunums ileums colons muscles golgi tissues atherosclerosis immunoblotting | |||
| 10218 | PCSK9 Monoclonal Antibody (Clone 15A6) | - |
|
2008-10-29 | 20.020184162063 | pcsk9-monoclonal-antibody-clone-15a6 | Proprotein Convertase Subtilisin Kexin 9; NARC-1 | antibodies proproteins serine protease lipoproteins LDLs low density neural apoptosis-regulated convertase 1 blotting ligands western immunoblotting WB blots | |||
| 10008811 | PCSK9 (murine) Polyclonal Antibody | - |
|
2007-01-22 | 15.063116022099 | pcsk9-murine-polyclonal-antibody | Proprotein Convertase Subtilisin Kexin 9; NARC-1 | immunoblot neural apoptosis regulated convertase 1 atherosclerosis proteins antibodies antisera antiserum WB western blots blotting ICC immunocytochemistry serines proteases lipoproteins subtilisin metabolisms mutations genes autosomal doimant dominance hypercholesterolemia low density LDLs overexpressions plasmas total cholesterols atherosclerosis PCSK-9 immunoblotting | |||
| 10240 | PCSK9 Polyclonal Antibody | - |
|
2009-07-21 | 7.141795580110 | pcsk9-polyclonal-antibody | NARC-1; Proprotein Convertase Subtilisin Kexin 9 | PCSK-9 PCSK 9 western blots ICC WB immunocytochemistry protease LDLs lipoproteins low-density low density cholesterol immunoblotting blotting | |||
| 10009567 | PCSK9 Western Ready Control | - | 2007-01-31 | 10.271860036832 | pcsk9-western-ready-control | Proprotein Convertase Subtilisin Kexin 9; NARC-1 | PSEC0052 subtilisin serine proteases LDLs low density lipoproteins cholesterol receptors golgi atherosclerosis | ||||
| 10010518 | PD 146176 | 4079-26-9 | ≥98% |
|
2009-02-25 | 78.610386740332 | pd-146176 | NSC 168807 | atherosclerosis 15-LOs 15-lipoxygenases oxidant injury injuries apoptosis amyloid β proteins inhibitors inhibits inhibitions Alzheimers disease oxidative stress pd146176 | ||
| 101707 |
PGC- |
- |
|
2005-10-12 | 33.914053239578 | pgc-1-polyclonal-antibody | PPARγ Coactivator 1; Peroxisome Proliferator-activated Receptor γ Coactivator 1 | atherosclerosis proteins diseases antibodies antisera antiserum WB western blots blotting IHC immunohistochemistry peroxisomes receptors gamma .gamma. PGC-1.beta. PGC-1.alpha. PRC N- C-terminus inducible transcriptional nuclear energy hepatic gluconeogenesis cholesterol homeostasis activates oxidative metabolisms tissues kidneys heart brown adipose skeletal muscles metabolic disorders type II 2 diabetes obesity endocrinology immunoblotting | |||
| 10044 | PGPC | 89947-79-5 | >98% |
|
2004-01-21 | 9.485155121122 | pgpc | PPAR.gamma. PPARgamma oxidized LDL lipds agonists atherosclerosis nuclear receptors thiazolidinediones sites peroxisome low-density lipoproteins e-selectin vcam1 vcam-1 binding | |||
| 10009926 | Phosphatidylcholine Assay Kit | - |
|
2007-07-10 | 71.825538674033 | phosphatidylcholine-assay-kit | PC Assay Kit | assays kits ceramides phospholipids atherosclerosis phosphorylcholines phosphocholines glycerol cells membranes fatty acids lipoproteins homeostasis sphingomyelin SM atherosclerosis atherosclerotic lesions serums plasmas quantifying quantification colorimetric PC PLD phospholipases | |||
| 19020 | Pinane Thromboxane A2 | 71111-01-8 | >98% |
|
16.813348066298 | pinane-thromboxane-a2 | PTA2; Pinane TXA2 | Thromboxanes analogs TXA2 antagonists TP receptors atherosclerosis | |||
| 10031 |
POV- |
121324-31-0 | >98% |
|
19.672787543947 | pov-pc | 2-(5-oxovaleryl) Phosphatidylcholine | oxidative injury lipids stress oxLDL oxidized low-density lipoproteins CD36 CD-36 PMNLs polymorphonuclear leukocytes atherosclerosis phosphatidylcholines scavengers receptors LPS-binding affinity potent structural determinant inhibits inhibition inhibitors lipopolysaccaride atherosclerosis | |||
| 10009088 | PPARα LBD (human recombinant) | - | >90% | 2006-09-13 | 12.125559392264 | ppar-lbd-human-recombinant | Peroxisome Proliferator-activated Receptor α Ligand Binding Domain | receptors PPAR.alpha.1 PPAR.alpha.2 PPARa1 PPARa2 Proteins Ligands domains PPAR's Ligand-activated transcription factors atherosclerosis endocrinology PPARalpha | |||
| 101710 | PPARα Polyclonal Antibody | - |
|
12.610607734806 | ppar-polyclonal-antibody | Peroxisome Proliferator-activated Receptor α | PPARa peroxisome proliferator-activated receptors PPARalpha antibodies PPAR.alpha. antisera nuclear receptors antiserum western blots blotting WB atherosclerosis endocrinology immunoblotting | ||||
| 10006915 | PPARα Transcription Factor Assay Kit | - |
|
2005-08-25 | 69.979846093133 | ppar-transcription-factor-assay-kit | Peroxisome Proliferator-activated Receptor α Transcription Factor Assay Kit | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARalpha PPAR.alpha. PPARa PPARα PPAR-α PPAR-alpha alpha a α .alpha. PPAR-.alpha. PPAR-a kits assys atherosclerosis endocrinology metabolic syndrom metabolism nuclear obese obesity transcription factors ligands hormones ELISA enzyme-linked enzyme linked immunosorbent EMSA electrophoretic mobility shifts PPRE response element adipokines TF | |||
| 10008878 | PPARα, δ, γ Complete Transcription Factor Assay Kit | - |
|
2006-08-22 | 51.581933701657 | ppar-complete-transcription-factor-assay-kit | PPARα PPARδ PPARγ PPAR-α PPAR-δ PPAR-γ PPAR α PPAR δ PPAR γ PPARalpha PPARdelta PPARgamma PPAR-alpha PPAR-delta PPAR-gamma delta alpha gamma PPAR.alpha. PPAR.delta. PPAR.gamma. PPAR-.alpha. PPAR-.delta. PPAR-.gamma. .alpha. .gamma. .delta.peroxisomes proliferator-activated proliferator activated receptors PPARs completes TF factors assay kits atherosclerosis endocrinology metaboli syndrome metabolism nuclear obese obesity PPAR non-radioacitve radioactive DNA detecting whole cells lysates 96-wells 96 wells immunosorbent ELISA enzyme-links enzyme-linked enzyme links linked electrophoretic mobility shifts EMSA double stranded dsDNA HRP colorimetric | ||||
| 61700 | PPARγ FL (human recombinant from E. coli) | - | >90% by SDS-PAGE | 2007-01-10 | 13.623030781373 | ppar-fl-human-recombinant-from-e-coli | Peroxisome Proliferator-activated Receptor γ Full Length (human recombinant) | proteins binding enzymes PPAR.gamma. PPARgamma diseases obesity diabetes atherosclerosis cancers endocrinology | |||
| 10009987 | PPARγ FL (human recombinant from Sf21 cells) | - | >80% by SDS-PAGE | 2007-06-15 | 17.833683241252 | ppar-fl-human-recombinant-from-sf21-cells | Peroxisome Proliferator-activated Receptor γ Full Length (human recombinant from Sf21 cells) | proteins binding enzymes PPAR.gamma. PPARgamma diseases obesity diabetes atherosclerosis cancers endocrinology | |||
| 10007685 |
PPARγ FP- |
- |
|
2009-07-16 | 60.499944751381 | ppar-fp-based-ligand-screening-assay-kit-green | Peroxisome Proliferator-activated Receptor γ FP-Based Ligand Screening Assay Kit - Green | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARgamma PPAR.gamma. PPARg PPARγ PPAR-γ PPAR-gamma gamma g γ .gamma. PPAR-.gamma. PPAR-g kits assys atherosclerosis TF diabetes drugs discovery discover endocrinology high throughput screens screening inflammations inhibitors inhibits inhibition metabolic syndromes metabolism nuclear receptors fluorescence FP-based FP based base ligands probes proteins isoforms γ1 γ2 γ-1 γ-2 1 2 adipose tissues colon immune systems retinas adipogenesis cells cellular differentiation insulin sensitization cancers fatty acids FAAH arachdionic 15-deoxy-DELTA12,14-prostaglandin 15-deoxy-DELTA12,14-PGs 15-deoxy-DELTA12,14-PGJ2 15 deoxy DELTA 12,14 PGs prostaglandins PGJ2 15-deoxy-Δ12,14-PGs 15-deoxy-Δ12,14-prostaglandins 15-deoxy-Δ12,14-PGJ2 15-deoxy-D12,14-prostaglandins 15-deoxy-D12,14-PGs 15-deoxy-D12,14-PGJ2 15-deoxy-.DELTA.12,14-prostaglandins 15-deoxy-.DELTA.12,14-PGs 15-deoxy-.DELTA.12,14-PGJ2 J2 thiazolidinediones TZD pioglitazone rosiglitazone agonists hyperglycemia hyperinsulinemia hypertriglyceridemia types 2 antidiabetics diabetes oral antagonists | |||
| 10007941 | PPARγ LBD (human recombinant) | - | >90% | 2006-03-16 | 24.550812943962 | ppar-lbd-human-recombinant | Peroxisome Proliferator-activated Receptor γ Ligand Binding Domain | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARgamma PPAR.gamma. PPARg PPARγ PPAR-γ PPAR-gamma gamma g γ .gamma. PPAR-.gamma. PPAR-g recombinant proteins atherosclerosis diabetes endocrinology genes regulations metabolic syndrome nuclear receptors obese obesity PPAR proteins biochemistry hexahistidine-tagged tagged hexahistidine HIS-tag HIS-tagged HIS N-terminal PPARalpha PPAR.alpha. PPARα PPAR-alpha PPAR-.alpha. PPAR-α PPAR-delta PPAR-.delta. PPAR-δ PPARdelta PPAR.delta. PPARδ hNUC1 FAAR pathology diseases cancers domains LBD ligand binds binding DNA DBD RXR acid-like acid like heterodimerization thiazolidinedione rosiglitazone piolitazone insulin type II E. coli coomassie stains staining western blots blotting immunoblotting WB fluorescent | |||
| 71000 | PPARγ Ligand Pack | - | >98% | 99.297845303867 | ppar-ligand-pack | Peroxisome Proliferator-activated Receptor γ Pack | ligands ppar.gamma. ppargamma receptors antagonists antidiabetic diabetes peroxisome nuclear receptors proliferator-activated 15-deoxy-delta12,14-PGJ2 rosiglitazone ciglitazone troglitazone MCC-555 MCC555 thiazolidinediones TZD GW9662 GW-9662 15-deoxy-d12,14-PGJ2 15-deoxy-.DELTA.12,14-PGJ2 nuclear receptors pioglitazone (potassium salt) 71740 18570 71742 70735 71745 10004272 GW 501516 GW501516 atherosclerosis packs | ||||
| 101700 | PPARγ Polyclonal Antibody | - |
|
15.482866428339 | ppar-polyclonal-antibody | Peroxisome Proliferator-activated Receptor γ | peroxisome proliferator-activated receptors PPARgamma1 PPARgamma2 antibodies PPARg1 PPARg2 PPAR.gamma.1 PPAR.gamma.2 antisera antiserum western blots blotting WB atherosclerosis endocrinology immunoblotting | ||||
| 10006855 | PPARγ Transcription Factor Assay Kit | - |
|
2005-08-25 | 83.255528111797 | ppar-transcription-factor-assay-kit | Peroxisome Proliferator-activated Receptor γ Transcription Factor Assay Kit | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARgamma PPAR.gamma. PPARg PPARγ PPAR-γ PPAR-gamma gamma g γ .gamma. PPAR-.gamma. PPAR-g kits assys atherosclerosis endocrinology metabolic syndrom metabolism nuclear obese obesity transcription factors ligands hormones ELISA enzyme-linked enzyme linked immunosorbent EMSA electrophoretic mobility shifts PPRE response element adipokines TF | |||
| 10007451 | PPARδ (human recombinant) | - | >95% | 2005-07-29 | 9.948187845304 | ppar-human-recombinant | PPARβ; Peroxisome Proliferative Activated Receptor δ; Nuclear Hormone Receptor 1; NUC1; FAAR | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARdelta PPAR.delta. PPARd PPARδ PPAR-δ PPAR-delta delta .delta. δ PPAR-.delta. PPAR-d recombinant proteins human atherosclerosis cancers EMSA electrophoretic mobility shift assays endocrinology fluorescence metabolic syndrome nuclear obese obesity biochemistry transcription factors members retionic acids genes expression developments baculovirus Sf21 heterodimerize subtypes hNUC1 FAAR ubiquitously tissues mediator embryo implantation overexpression systems gels coomassie stains staining western blots WB immunoblotting 10006914 | |||
| 101720 | PPARδ Polyclonal Antibody | - |
|
2004-11-05 | 15.819088397790 | ppar-polyclonal-antibody | Nuclear Hormone Receptor 1; NUC1; FAAR; PPARβ | PPAR.delta. PPAR.beta. PPARbeta peroxisome proliferator-activated receptors PPARdelta antibodies antisera nuclear receptors antiserum western blots blotting WB ICC immunocytochemistry IHC immunohistochemistry atherosclerosis endocrinology immunoblotting | |||
| 10006914 | PPARδ Transcription Factor Assay Kit | - |
|
2005-08-23 | 49.096223362273 | ppar-transcription-factor-assay-kit | Peroxisome Proliferator-activated Receptor δ Transcription Factor Assay Kit | peroxisomes proliferator-activated receptors PPARs proliferator activated PPARdelta PPAR.delta. PPARd PPARδ PPAR-δ PPAR-delta delta .delta. δ PPAR-.delta. PPAR-d kits assys atherosclerosis endocrinology metabolic syndrom metabolism nuclear obese obesity transcription factors ligands hormones ELISA enzyme-linked enzyme linked immunosorbent EMSA electrophoretic mobility shifts PPRE response element adipokines TF | |||
| 10009568 | PPARδ Western Ready Control | - | 2007-02-02 | 7.238066298342 | ppar-western-ready-control | Peroxisome Proliferative Activated Receptor δ; Nuclear Hormone Receptor 1; FAAR; PPARβ; NUC1 | peroxisome proliferative-activated receptor PPARd xenopus laevis PPARb PPAR.beta. liver intesine kidney abdominal adipose skeletal muscle lipids metabolism cholesterol homeostasis embryos cancers obesity atherosclerosis endocrinology | ||||
| 10010343 | Pravastatin (sodium salt) | 81131-70-6 | >98% |
|
2008-03-04 | 14.347620363062 | pravastatin-sodium-salt | atherosclerosis HMGCoA HMG-CoA reductase LDL-c HDL-c statins cholesterol heart diseases CVD pravachol lipostat inhibitors inhibits inhibitions cardiovascular | |||
| 10011724 |
Propenyl- |
- | >90% |
|
✓ | 2008-08-19 | 9.454972375691 | propenyl-l-nio-hydrochloride | ENIPO | nitric oxide synthase NOS iNOS selective inhibitors inhibits inhibition | |
| 10008841 | Propylpyrazole Triol | 263717-53-9 | >98% |
|
2007-01-25 | 101.922580899763 | propylpyrazole-triol | PPT | 17b-estrogen 17beta-estrogen 17.beta.-estrogen receptors ERalpha ER.alpha. ERbeta ER.beta. agonist ischemia DPN diarylpropinitrile in vivo infarct endocrinology | ||
| 13010 | Prostaglandin E1 | 745-65-3 | >98% |
|
69.748572259377 | prostaglandin-e1 | Alprostadil; PGE1 | PGE1 vasodilation atherosclerosis erectile dysfunction prostaglandins pharma:1 | |||
| 313010 |
Prostaglandin E1- |
- | ≥99% deuterated product |
|
26.165009208103 | prostaglandin-e1-d4 | Alprostadil-d4; PGE1-d4 | GC/MS deuterium isotopes PGE1-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry atherosclerosis | |||
| 17020 | Prostaglandin H2 | 42935-17-1 | >95% |
|
249.773941068140 | prostaglandin-h2 | PGH2 | PGH2 endoperoxides cyclooxygenase vasoconstrictors prostaglandins PGHS2 syntahses cox-2 cox2 PGHS-2 atherosclerosis | |||
| 18220 | Prostaglandin I2 (sodium salt) | 61849-14-7 | >99% |
|
69.614456721915 | prostaglandin-i2-sodium-salt | Prostacyclin (sodium salt); Epoprostenol (sodium salt); PGI2 (Na salt) | PGI2 metabolites prostaglandins salts Na+ COX cyclooxygenases atherosclerosis | |||
| 18300 | Prostaglandin I3 (sodium salt) | 68324-96-9 | >99% |
|
67.804143646409 | prostaglandin-i3-sodium-salt | PGI3 (Na salt) | w-3 omega-3 PGI3 prostaglandins atherosclerosis .omega.-3 salts Na+ | |||
| 160630 |
Prostaglandin I Synthase Monoclonal Antibody (Clone isn- |
- | 6.660718232044 | prostaglandin-i-synthase-monoclonal-antibody-clone-isn-1 | Prostacyclin Synthase; PGIS; PGI Synthase | synthases endothelium PGI2 prostaglandins antibodies antisera antiserum Bovine PGI synthase atherosclerosis neurochemistry IP immunoprecipitation IHC immunohistochemistry | |||||
| 100023 | Prostaglandin I Synthase (murine) Polyclonal Antibody | - |
|
2004-06-30 | 9.757941988950 | prostaglandin-i-synthase-murine-polyclonal-antibody | PGIS; Prostacyclin Synthase; PGI Synthase | antibodies antisera antiserum western blots blotting wb IHC immunohistochemistry prostaglandins prostacyclins synthases receptors atherosclerosis immunoblotting | |||
| 160640 | Prostaglandin I Synthase Polyclonal Antibody | - | 7.291952117864 | prostaglandin-i-synthase-polyclonal-antibody | Prostacyclin Synthase; PGIS; PGI Synthase | PGIS prostacyclin synthases endothelium Western blots PGI2 prostaglandins blotting antisera antiserum immunoprecipitation IP antibodies atherosclerosis WB immunoblotting | |||||
| 13294 | Pyrrophenone Exclusive New | 341973-06-6 | ≥90% |
|
✓ | 2010-04-07 | 51.367941988950 | pyrrophenone | phospholipase A2 group IVA phospholipase A2 PLA2 cytosolic PLA2 cPLA2 arachidonic acid AA prostaglandins PG leukotrienes LT inhibitors PGE2 LTB4 blood secretory type PLA2 sPLA2 inflammation inhibition inhibits inflammatory | ||
| 10006217 | Renin (human recombinant) | - | >99% by SDS-PAGE | 2004-12-13 | 75.871298342541 | renin-human-recombinant | enzymes aspartyl proteases angiotensins II glycoproteins angiotensinogen salt balance hypertension angiotensinogens kidney renal preprorenin atherosclerosis endocrinology | ||||
| 10006270 | Renin Inhibitor Screening Assay Kit | - |
|
2005-05-04 | 64.085943172849 | renin-inhibitor-screening-assay-kit | Protease measurement assays aspartyl renal juxtaglomerular cells sodium depletion blood volume pressure .beta.-adrenergic stimulation angiotensinogens angiotensins I II converting ACE monomeric zinc metalloenzymes vascular endothelium messengers RAS vasoconstrictor peripheral hypertension receptors blockers fluorescence fluorescent fluorometric atherosclerosis endocrinology | ||||
| 10012554 | Resolvin D1 Exclusive | 872993-05-0 | ≥95% |
|
✓ | 2008-06-06 | 349.448176795580 | resolvin-d1 | RvD1; 17(S)-Resolvin D1 | EPA DHA inflammation antiinflammatory anti-inflammatory immune responses aspirin LOX peritonitis LOS neurochemistry resolvins | |
| 10006415 |
Ro 48- |
161582-11-2 | >98% |
|
2005-06-01 | 30.147645027624 | ro-48-8071 | monooxidosqualenes cyclases inhibitors OSC cholesterols lowering activity microsomal enzymes catalyzes lanosterol synthetic pathway LDL low-density lipoproteins human livers microsomes HepG2 cells HDL high-desity toxicity CYP3A mRNA proteins hepatocytes cultures atherosclerosis | |||
| 71740 | Rosiglitazone | 122320-73-4 | >98% |
|
343.735160220994 | rosiglitazone | BRL 49653 | BRL49653 BRL-49653 ligands ppar.gamma. ppargamma receptors antagonists antidiabetic nuclear receptors diabetes peroxisome atherosclerosis endocrinology | |||
| 10011343 |
Rosiglitazone- |
- | >99% deuterated product |
|
2009-04-04 | 207.046933701657 | rosiglitazone-d5-maleate | SPI TZDs thiazolinedions PPARg PPAR.gamma. PPARgamma selective ligand insulin resistance anti-inflammatory | |||
| 71742 | Rosiglitazone (potassium salt) | 316371-84-3 | >98% |
|
161.052417127072 | rosiglitazone-potassium-salt | BRL49653 BRL-49653 ligands ppar.gamma. ppargamma receptors antagonists antidiabetic nuclear receptors diabetes peroxisome salts thiazolidinediones atherosclerosis endocrinology | ||||
| 10005260 | Serine Palmitoyltransferase Polyclonal Antibody | - |
|
2004-12-02 | 14.222235727440 | serine-palmitoyltransferase-polyclonal-antibody | Serine-palmitoyl-CoA transferase, long chain base subunit 2; SPT | antibodies antisera western blots blotting WB sphingolipids SPT2 immunohistochemistry immunohistochemical analysis IHC nuclear proteins nucleus immunoblotting | |||
| 10007681 | Serum Retinol Binding Protein 4 Polyclonal Antibody Exclusive | - |
|
✓ | 2007-08-03 | 4.897116022099 | serum-retinol-binding-protein-4-polyclonal-antibody | Plasma Retinol Binding Protein 4; pRBP; sRBP4 | vitamin A wb western blotting type 2 diabetes lipocalin TTR transthyretin sRBP4 sRBP-4 proteins adipocytes signals signalling signaling insulin blots retinols serums RBP atherosclerosis endocrinology immunoblotting | ||
| 10010344 | Simvastatin | 79902-63-9 | >98% |
|
2008-02-27 | 30.723003157064 | simvastatin | MK 733 | HMG-CoA reductase HMGCoA inhibits inhibitors inhibition LDL-c HDL-c statins cholesterol heart diseases CVD atherosclerosis zocor zetia exetimibe vytorin inegy TNF-.alpha. NF-.kappa.B apoptosis cancers cardiovascular NFkB atherosclerosis | ||
| 10010146 | Soluble Epoxide Hydrolase Polyclonal Antibody | - |
|
2008-03-03 | 15.367648480662 | soluble-epoxide-hydrolase-polyclonal-antibody | Epoxide Hydrolase 2; EPHX2; sEH; Cytosolic Epoxide Hydrolase (CEH) | metabolism hypertension inflammation EpETrEs EETs DiHETrEs DHET inhibitors inhibit inhibitions epoxyeicosatrienoic acids eicosatrienoic WB western blots blotting immunoblotting | |||
| 10006964 | Sphingomyelinase Assay Kit | - |
|
2009-11-25 | 43.334290821301 | sphingomyelinase-assay-kit | SMase Assay Kit | sphingomyelinases SMases hydrolases enzymes sphingolipids metabolisms DNases I superfamily sphingomyelins phosphorylcholines ceramides cells cellular stress cations lysosomal acids secreted zinc-dependent membrane-bound magnesium-dependent neutral cytosolic magnesium-independent neutral alkalines mutations ASM genes Type A B Niemann-Pick diseases physiological pathophysiological lysosomal digestion neuronal vascular ceramide-mediated signal transduction cytokine-induced apoptosis differentiation immune inflammatory lipoproteins aggregation vessel walls atherogenesis intracellular cholesterol trafficking metabolism assays kits measures measuring measurements acidic activity tissues homogenates lysates serum blood saliva urine coupled enzymatic reactions oxidases betaine h2o2 hydrogen peroxides horseradish peroxidases HRPs 10-acetyl-3,7-dihydroxyphenozazine ADHP fluorescent fluorescence | |||
| 700330 | Sphingomyelinase Inhibitor Screening Assay Kit | - |
|
2010-02-09 | 90.860927587085 | sphingomyelinase-inhibitor-screening-assay-kit | assays kits measures measuring measurementsphingomyelinases SMases hydrolases enzymes sphingolipids metabolisms DNase I superfamily phosphocholines ceramides cellular cells stress pathophysiological lysosomal digestion ceramide-mediated signal transductions cytokine-induced apoptosis differentiation immune inflammatory lipoproteins aggregation vessels atherogenesis intracellular cholesterols trafficking acidic neutral proliferation depressive disorders neurodegenerative disorders strokes Alzheimer's dementia diseases therapeutics cleavage conjugates free thiols | ||||
| 19025 | SQ 29,548 | 98672-91-4 | ≥98% |
|
146.517099447513 | sq-29-548 | thromboxanes TXA2 SQ-29548 SQ29548 analogs TP antagonists receptors atherosclerosis | ||||
| 10010854 |
SREBP- |
- |
|
2008-06-24 | 32.293178420539 | srebp-1-transcription-factor-assay-kit | Sterol Regulatory Element-Binding Protein-1 Assay Kit | tf atherosclerosis SREBPs sterols regulatory element binding proteins factors basic helix-loop-helix-leucine zipper family expression regulate synthesis regulation uptake cholesterol fatty acids triglycerides phospholipids adipocyte differentiation insulin-dependent genes SREBP-1a membrane-bound rough ER endoplasmic reticulum cleavage activating SREBP-Scap Golgi proteolytic two-step cleavage S1P S2P NH2 -terminal active domain nuclear localization signal importin nucleus upregulating genes fatty acids lipogenic enzymes acetyl CoA coenzymes A carboxylases synthases long chain elongases glucose glucokinases glycolysis diseases obesity diabetes mellitus insulin resistance non-alcoholic liver non-radioactive sensitve sensitivity detects detecting double stranded dsDNA extracts ELISA EMSA humans rats mouse mice murine SREBP1C SREBP 1c assays | |||
| 10009266 |
SREBP- |
- | 2006-10-18 | 43.027085635359 | srebp-2-blocking-peptide | SREBF2; Sterol Regulatory Element-binding Transcription Factor 2; Sterol Regulatory Element-binding Protein-2 | signaling signalling controls peptides proteins diseases antibodies antisera antiserum WB western blots blotting ICC immunocytochemistry atherosclerosis 1a 1c basic helix-loop-helix bHLH transcription factors lipids homeostasis regulating genes cholesterols fatty acids metabolisms domains amino-terminals hydrophobic regions transmembranes segments carboxy regluates synthesis genes HMG-CoA reductases enzymes synthetics pathways tissues basal ER endoplasmic reticulum membranes glycosylateds nucleus cells livers brown fats testis HepG2 human fibroblasts | ||||
| 10009239 |
SREBP- |
- |
|
2007-04-17 | 27.773281767955 | srebp-2-cell-based-translocation-assay-kit | Sterol Regulatory Element-Binding Protein-2 Cell-Based Translocation Assay Kit | sterol regulatory element binding proteins athersclerosis cholesterols fatty acids triglycerides phospholipids helix-loop-helix HLH transcription factors DyLight Pierce Biotechnology assays fluorescence fluorescent fluorometric cell-based assays cell based assay cba | |||
| 10007663 |
SREBP- |
- |
|
2006-02-22 | 77.802662983425 | srebp-2-polyclonal-antibody | Sterol Regulatory Element-binding Transcription Factor 2; SREBF2; Sterol Regulatory Element-binding Protein-2 | atherosclerosis proteins diseases antibodies antisera antiserum WB western blots blotting ICC immunocytochemistry 1a 1c basic helix-loop-helix bHLH transcription factors lipids homeostasis regulating genes cholesterols fatty acids metabolisms domains amino-terminals hydrophobic regions transmembranes segments carboxy regluates synthesis genes HMG-CoA reductases enzymes synthetics pathways tissues basal ER endoplasmic reticulum membranes glycosylateds proteins nucleus cells livers brown fats testis HepG2 human fibroblasts endocrinology immunoblotting | |||
| 10007819 |
SREBP- |
- |
|
2006-09-20 | 26.722014449638 | srebp-2-transcription-factor-assay-kit | Sterol Regulatory Element-binding Protein-2 Assay Kit | tf sterol regulatory element binding proteins cholesterol fatty acids triglycerides phospholipids atherosclerosis assays | |||
| 10009749 |
SREBP- |
- | 94 kDa (GST-tagged); 68 kDa (native) | 2007-07-30 | 17.977790055248 | srebp-2-western-ready-control | Sterol Regulatory Element-binding Transcription Factor 2; Sterol Regulatory Element-binding Protein 2; SREBPF2 | WB western blot helix loop bHLH fatty acids genes cholesterol regulatory HMG-CoA tissues E. coli SREBP2 SREBPF-2 transcription factors SREBP 2 atherosclerosis | |||
| 10011298 | Stearic Acid | 57-11-4 | >98% |
|
2008-10-10 | 2.838093922652 | stearic-acid | saturated fatty acids trans LDLs HDLs liporotein cholesterols dietary fats atherosclerosis | |||
| 10026 | T0070907 | 313516-66-4 | >98% |
|
92.303651933701 | t0070907 | T-0070907 nuclear receptors antagonist PPARgamma PPAR.gamma. peroxisome proliferator-activated selective selectivity thiazolidinediones TZDs inhibits inhibition inhibitors atherosclerosis endocrinology | ||||
| 71810 | T0901317 | 293754-55-9 | >98% |
|
187.846201657458 | t0901317 | agonists to901317 TO-901317 T-0901317 t0-901317 receptors lipid nuclear hormone LXR.alpha.nuclear receptors LXR.beta. LXRalpha LXRbeta atherosclerosis | ||||
| 10009911 | Tangeritin | 481-53-8 | ≥98% |
|
2008-12-16 | 5.877348066298 | tangeritin | Ponkanetin; NSC 618905; NSC 53909 | flavone cancers tumors cholesterol atherosclerosis ERKs p38 MAPKs JNKs AKTs LDLs triacylglycerol estradiol MDR1 pregnane X receptors IL-1 IL1 IL 1 melanoma insulinoma | ||
| 10007349 |
TGX- |
663619-89-4 | >98% |
|
2006-02-21 | 56.985778355540 | tgx-221 | phosphatidylinositol-3-kinases PI3K catalyzes phosphorylation produces second messengers (3,4)-biphosphates -P2 (3,4,5)-P3 Class 1 p110.alpha. .beta. .delta. .gamma. p85 regulatory subunits cells permeable inhibitors inhibition inhibits ATP binding sites platelets defective thrombus formation antithrombotic therapy atherosclerosis | |||
| 19030 | Thromboxane B2 | 54397-85-2 | ≥99% |
|
35.410765588003 | thromboxane-b2 | TXB2 | thromboxanes platelets metabolites TXB2 intrarenal TXA2 urine urinary atherosclerosis | |||
| 160720 |
Thromboxane B2 11- |
- | 34.875049723757 | thromboxane-b2-11-dehydrogenase-polyclonal-antiserum | TXB2 11-dehydrogenase | Western blots blotting erythrocyte thromboxanes TXB2 antisera antibodies antiserum WB atherosclerosis immunoblotting | |||||
| 319030 |
Thromboxane B2- |
- | ≥99% deuterated product |
|
26.226372007366 | thromboxane-b2-d4 | TXB2-d4 | GC/MS deuterium isotopes internal standards GC-MS LC/MS LC-MS mass spectrometry atherosclerosis prostaglandins TXB2-d4 thromboxanes deuterated | |||
| 519031 | Thromboxane B2 EIA Kit | - |
|
468.072524861878 | thromboxane-b2-eia-kit | TXB2 thromboxanes measures kits eias enzyme atherosclerosis immunoassays ELISAs assays | |||||
| 10004023 |
Thromboxane B2 Express EIA Kit - |
- |
|
2004-07-02 | 180.263563535911 | thromboxane-b2-express-eia-kit-monoclonal | TXB2 Express ELISA Kit - Monoclonal; TXB2 Express EIA Kit (Monoclonal) | solid plates atherosclerosis thromboxanes measures kits eias enzyme immunoassays ELISAs intrarenal TXA2 synthesis fast same-day assays | |||
| 10007237 | Thromboxane B2 Lipid Maps MS Standard | 54397-85-2 | ≥99% |
|
2009-01-16 | 15.506095764273 | thromboxane-b2-lipid-maps-ms-standard | TXB2 | thromboxanes platelets metabolites TXB2 intrarenal TXA2 urine urinary atherosclerosis MS mass spectrometry standards | ||
| 19990 | Thromboxane B3 | 71953-80-5 | >98% |
|
9.805801104972 | thromboxane-b3 | TXB3; Δ17-TXB2 | .DELTA.17-TXB2 Thromboxanes TXB3 TXA3 omega-3 .omega.-3 w-3 d17-TXB2 DELTA17-TXB2 atherosclerosis | |||
| 160715 | Thromboxane Synthase Polyclonal Antibody | - |
|
17.735359116022 | thromboxane-synthase-polyclonal-antibody | TX Synthase | prostaglandins PGH2 platelet aggregation thromboxanes TXS Synthases western blots blotting WB antibodies antisera antiserum IHC immunohistochemistry atherosclerosis immunoblotting | ||||
| 10005263 | TOFA | 54857-86-2 | >98% |
|
2004-07-28 | 20.117458563536 | tofa | RMI 14514; 5-(Tetradecyloxy)-2-Furoic Acid | inhibits inhibitors inhibition ACC acetyl-CoA carboxylases fatty acid synthases synthesis FAS cerulenin apoptosis cancer C75 malonyl-CoA atherosclerosis endocrinology | ||
| 10004452 | TP Receptor (human) Polyclonal Antibody | - |
|
2004-04-01 | 100.295502762431 | tp-receptor-human-polyclonal-antibody | TXA2 Receptor Polyclonal Antibody; Thromboxane A2 Receptor Polyclonal Antibody | thromboxanes platelets metabolites TXA2 IHC immunohistochemistry antibodies antisera antiserum western blot blotting WB atherosclerosis immunoblotting ICC immunocytochemistry | |||
| 10012559 | TP Receptor (human) Polyclonal FITC Antibody | - | 2008-07-25 | 70.520841006752 | tp-receptor-human-polyclonal-fitc-antibody | TXA2 Receptor; Thromboxane A2 Receptor | antibodies antiserum antisera thromboxane A2 TXA2 receptors flow cytometry FC IFimmunofluorescence western blots blotting WB immunoblotting | ||||
| 13044 | Tranilast | 53902-12-8 | ≥98% |
|
2008-08-29 | 14.231767955801 | tranilast | SB 252218; Rizaben; MK 341; Tranpro; N-(3',4'-Dimethyoxycinnamoyl)Anthranilic Acid | anti-inflammatory antiinflammatory angiogenesis PGDF TGF-.beta.1 TGF.beta.1 IL-8 IL8 PGE2 TXB2 antiallergenic anti-allergenic atherosclerosis vascular disease VEGF | ||
| 70675 |
trans- |
501-36-0 | >98% |
|
54.732535911601 | trans-resveratrol | (E)-Resveratrol | selective cyclooxygenases inhibitors COX-1 PGHS-1 COX1 PGHS1 prostaglandins H synthases 1 antioxidants oxidative injury stress atherosclerosis sirtuins 3,5,4'-trihydroxystilbene 3,5,4'-trihydroxy-trans-stilbene 3,5,4'-THS 3,5,4'-trimethoxy stilbene 3,5,4'-trimethoxystilbene (E)-stilbenes | |||
| 13130 |
trans- |
- | ≥99% deuterated product |
|
2009-01-14 | 19.885392265193 | trans-resveratrol-d4 | (E)-Resveratrol-d4 | selective cyclooxygenases inhibitors COX-1 PGHS-1 COX1 PGHS1 prostaglandins H synthases 1 antioxidants oxidative injury stress atherosclerosis deuterated LC/MS GC-MS LC-MS mass spectrometry deuterium sirtuins | ||
| 10162 | Treprostinil | 81846-19-7 | >98% |
|
2005-08-30 | 107.833449969306 | treprostinil | primary pulmonary hypertension PPH arterial vascular resistance stable analogs prostacyclins increase plasma half-life vasodilatory inhibits inflammatory cytokines inhibition inhibitors GM-CF human alveolar macrophages NF-KB NF-.kappa. translocations nucleus NF-kappaB nfkb nf-kb NF-.kappa.B atherosclerosis | |||
| 71750 | Troglitazone | 97322-87-7 | >98% |
|
141.123370165745 | troglitazone | ResulinTM | antidiabetic thiazolidinediones PPAR.gamma. PPARgamma ligands selective peroxisome proliferator-activated receptors diabetes TZD Resulin nuclear receptors atherosclerosis endocrinology | |||
| 10009085 |
U- |
3039-71-2 | >95% |
|
2007-01-19 | 25.601878453038 | u-18666a | Niemann-Pick type C NPC apoptosis neuronal death Alzheimers AD neurodegeneratives diseases trafficking unesterified ER cells membranes cateracts epilepsy Free cholesterol loading NSC 70801 Endoplasmic reticulum atherosclerosis inhibits inhibitors inhibition endosomes lysomes oxidosqualene cyclases atherosclerosis | |||
| 16440 |
U- |
56985-32-1 | >98% |
|
2.279060773480 | u-44069 | 9,11-dideoxy-9α,11α-epoxymethano Prostaglandin F2α; 9,11-dideoxy-9α,11α-epoxymethano PGF2α; 9,11-epoxymethano Prostaglandin H2 | endoperoxides methanoepoxy PGH2 thromboxanes analogs prostaglandins U44069 TP receptors agonists atherosclerosis | |||
| 16450 |
U- |
56985-40-1 | >98% |
|
297.350271220492 | u-46619 | 9,11-dideoxy-9α,11α-methanoepoxy Prostaglandin F2α; 9,11-dideoxy-9α,11α-methanoepoxy PGF2α | endoperoxides PGH2 thromboxanes vasoconstriction analogs TP receptors agonists U46619 atherosclerosis | |||
| 16465 |
U- |
64192-56-9 | >98% |
|
95.548103130755 | u-51605 | diazo endoperoxides inhibitors U51605 analogs PGH2 PGIs synthase prostaglandins inhibits thromboxanes atherosclerosis | ||||
| 10003 | Vasoactive Eicosanoid HPLC Mixture | - | >98% for each compound | 19.415613259668 | vasoactive-eicosanoid-hplc-mixture | 11-dehydro-TXB2 2,3-dinor-6-keto-PGF1.alpha. 2,3-dinor-6-keto-PGF1alpha 2,3-dinor-TXB2 12-HHTs 12(S)-HHTrEs 12-HHTrEs 12(S)HHTrEs thromboxanes prostaglandins eicosanoids mixtures 2,3-dinor-PGF1.alpha. 2,3-dinor-PGF1alpha chromatography atherosclerosis | |||||
| 70730 | Wy 14643 | 50892-23-4 | >98% |
|
123.218149171270 | wy-14643 | Pirinixic Acid | activators peroxisome proliferator-activated receptors adipocytes obesity PPARalpha PPAR. nuclear receptors alpha. PPARgamma PPAR.gamma. PPARdelta PPAR.delta. atherosclerosis endocrinology wy14643 | |||
| 18113 |
YM- |
182959-33-7 | ≥98% |
|
✓ | 2009-08-11 | 32.830607734807 | ym-53601 | squalene synthases inhibitors cholesterol triglycerides HMG-CoA reductase fibrates hyperlipidemia hypercholesterolemia lipid-lowering activities inhibitor inhibited | ||
| 71800 |
(Z)- |
39025-23-5 | ≥98% |
|
2009-12-01 | 1.714984453480 | -z-guggulsterone | anti flammatory cancers FXR bile acids LDL cholesterol tumors IL-6 STAT3 VEGF Akt | |||
| 90210 |
α- |
463-40-1 | >98% |
|
8.872304656669 | -linolenic-acid | ALA | fatty acids PUFAs omega-3 .omega.-3 polyunsaturated w-3 essential leafy green vegetables alpha-linolenic .alpha.-linolenic | |||
| 16460 |
Δ17- |
- | >98% |
|
132.353370165745 | -17-u-46619 | d17-u-46619 delta17-u-46619 .delta.17-u-46619 thromboxanes TXA3 analogs agonists d17-u46619 delta17-u46619 .delta.17-u46619 atherosclerosis |
Cayman Chemical Company · 1180 East Ellsworth Road · Ann Arbor, Michigan 48108 · USA
Toll Free: (800) 364-9897 (USA and Canada Only) · Fax: (734) 971-3640
Copyright 2010 Cayman Chemical Company
Quick Search